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ABSTRACT OF THE DISSERTATION
Role of VimF in Gingipain Maturation in Porphyromonas gingivalis
By
Arun S Muthiah
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, September 2013
Dr. Hansel M. Fletcher, Chairperson

Gingipain activity in Porphyromonas gingivalis, the major etiological agent in
adult periodontitis, is post-translationally regulated by unique Vim proteins including
VimF, a putative glycosyltransferase. To ascertain the VimF mediated phenotype we first
inactivated the vimF gene in P. gingivalis ATCC 33277 (FLL476), a less virulent
fimbriated strain. We observed that the vimF-defective mutant (FLL476) showed a
phenotype similar to that of the vimF-defective mutant (FLL95) in the P. gingivalis W83
background. While hemagglutination was not detected and autoaggregationn was
reduced, biofilm formation was increased in FLL476. Also, invasive capacity decreased
for this mutant. Furthermore, fimbrial structures were missing in FLL476, suggesting the
role of VimF in fimbrial processing. We were able to restore the wildtype phenotype by
complementing the defect. Secondly, we cloned, expressed and purified the vimF gene
and demonstrated its ability to glycosylate gingipains. In vitro glycosyltransferase
activity for rVimF was observed using UDP-galactose and N-acetylglucosamine as donor
and acceptor substrates, respectively. Further, in the presence of rVimF and UDPgalactose, a 60 kDa protein from the extracellular fraction of FLL95 which was identified
my mass spectrometry as Rgp gingipain, immunoreacted with the glycan specific mAb
IB5 antibody. Finally, the polyclonal antibody raised against rVimF that did not react

xvii

well with native VimF from P. gingilvalis, reacted with a 47 kDa protein when the
fractions were first deglycosylated before probing with the antibody. Galactose is vital
for growing glycan chain leading to maturation/activation of gingipains. Taken together,
these results suggest that VimF glycoprotein is a galactosyltransferase that may be
specific for gingipain glycosylation.
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CHAPTER ONE
INTRODUCTION

Bacteria and Oral Cavity
Bacteria inherently have the ability to colonize various anatomical locations of the
human body living either as commensals or pathogens. Pathogenic bacteria are able to
overcome host-mediated resistance and establish infection. Oral cavity is colonized with
over 700 different species of bacteria, most of which are not cultivated yet [1,2]. Most of
the cultivated bacteria belong to the phyla Actinobacteria, Bacteroidetes, Firmicutes,
Proteobacteria, Spirochaetes, Synergistetes and Tenericutes [2]. Two major bacteria
mediated infections of the oral cavity are dental carries and periodontal infections.
Bacteria that are able to produce copious amounts of acids and dissolve minerals of the
teeth cause dental decay. Although transient, loss of minerals is replenished by the flow
of saliva, and frequent consumption of sugary food ensures sustained acid production
causing this loss. Streptococcus mutant and Lactobacilli are primary bacteria implicated
in dental carries[3]. On the other hand periodontal disease is mediated by organism that
are mostly asaccharolytic but able to produce potent proteases which mediate destruction
of the periodontium [4]. Periodontal disease begins with periodontal pockets, which offer
a favorable niche for colonization by periodontal bacteria leading to forming plaques.
While early colonizers of plaques are generally Gram-positive organism and nonpathogenic, late colonizer are predominantly Gram-negative and pathogenic [5].
Porphyromonas gingivalis is implicated in adult periodontitis along with two other red
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complex organism namely Tanarella forsythia and Treponema denticola.
Aggregatibacter actinomycetemcommitans is associated with localized aggressive
periodontitis [6]. These bacteria are all Gram negative, anaerobic and asaccharolytic, with
virulence factors that include an array of proteolytic enzymes [7]. P. gingivalis is
considered to be the most important agent causing adult periodontitis [8,9]. Although
caries and periodontitis are clearly bacterial diseases, they are not infectious diseases in
the classical sense because they result from a complex interaction between the
commensal microbiota, host susceptibility and environmental factors such as diet and
smoking.
P. gingivalis is now recognized as a keystone microorganism of the oral
microflora [10]. This is due to their ability in the oral cavity to both survive as
commensal and, at times cause infection using its various pathogenic factors. Recently it
was shown that P. gingivalis, even at low colonization levels could influence other oral
commensals toward an inflammatory environment leading to bone loss. On the other
hand, studies using mice model show that P. gingivalis by itself is unable to induce
disease [11]. Together with the fact that P. gingivalis is present as normal flora in healthy
individuals [12,13], suggest that pathogenic potential of this organism is not only due to
its pathogenic potential but also related to physiological state of the host and association
with other oral microbiome [14].

Progression of Periodontal Disease
Periodontal disease develops when the gum gets detached from the teeth due to
inflammation mediated by formation of plaques. This invisible, sticky film forms on teeth
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when starches and sugars in food interact with bacteria normally found in mouth.
Periodical brushing and flossing removes plaques but it re-forms quickly, usually within
24 hours. Plaque that stays on teeth longer than two or three days can harden under the
gum-line into tartar (calculus), a white substance that makes plaque more difficult to
remove and that acts as a reservoir for bacteria. Initially, plaques may simply irritate and
inflame the gingiva, causing gingivitis, the mildest form of periodontal disease. But
unchecked ongoing inflammation eventually causes pockets to develop between gums
and teeth that fill with plaque, tartar and bacteria. In time, the pockets become deeper and
more bacteria accumulate, eventually advancing under gum line. The progressive
infection around the teeth leads to loss of tissue and bone ultimately causing exfoliation
of the teeth. While gingivitis is prevalent on an average of 3-4 teeth in 50% of adult
population in the United States, adult periodontitis, as defined by pocket depth of >4mm
seen on an average of 3-4 teeth in 30% of the adult population. Plaque bacteria elaborate
various compounds (H2S, NH3, amines, toxins, enzymes, antigens, etc.) that elicit an
inflammatory response. This response is usually protective but excessive cytokines
produced by an over reacting immune system can cause damage to host tissue leading to
loss of periodontal tissue, pocket formation, and loosening and loss of teeth. In addition
white blood cells, in response to the plaque, release a family of enzyme called matrix
metalloproteinases (MMPs), which are responsible for break down of connective tissue.
Other studies using animal models have documented host genetic factors [15] that play a
role in causing periodontal disease. In this introduction, I will explore various virulence
factors produced by Porphyromonas gingivalis and specifically focus on proteases and
their role in pathogenesis.
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Anatomy of the Periodontium
The main function of the periodontium is to attach the tooth to the bone tissue of
the jaws and to maintain the integrity of the surface of the masticatory mucosa of the oral
cavity. The periodontium comprises of the following structures – gingiva, periodontal
ligaments, root cementum and alveolar bone [See Fig. 1] The gingiva is that part of the
masticatory mucosa which covers the alveolar process and surrounds the cervical portion
of the teeth. It consists of an epithelial layer and an underlying connective tissue layer
called the lamina propria. Two parts of the gingiva are the free gingiva and attached
gingiva. Between the free gingiva and the tooth is the gingival sulcus. The gingival
epithelium is a stratified squamous epithelium that is an interface between the external
environment, which is exposed to bacterial challenges, and the underlying periodontal
tissue. The periodontal ligament is an unmineralized connective tissue located between
cementum and alveolar bone functioning to sustain the teeth within the jaw and
facilitating movement between tooth and bone [16]. Cells of the periodontal ligament are
involved in maintenance, repair and regeneration of periodontal tissue. Thus these cells
are multipotent composed of heterogeneous cell populations including fibroblasts that can
differentiate into either cementum-forming cementoblasts or bone-forming osteoblasts
[16]. The cementum is a specialized mineralized tissue covering the root surfaces having
many features common to the bone but devoid of blood, lymph and nerve supply.
Although it does not undergo physiologic resorption or remodeling like the bone, it is
characterized by continual deposition throughout life. Cementum is present in two forms,
the acellular extrinsic fiber cementum covering the upper portion of the root and cellular
intrinsic fiber cementum covering the lower apical root region. While the acellular
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cementum is critical for tooth attachment to the adjacent periodontal ligaments, the
cellular cementum containing cementocytes is thought to contribute to the process of
repair after damage to the root surface [17]. Alveolar process (alveolar bone) is that
portion of maxilla and mandible that supports the roots and disappears if the teeth are
lost. It is composed of two parts: the alveolar bone proper that lines the tooth sockets and
the supporting bone constituting the rest of bone. The main function of alveolar bone is to
distribute and resorb forces generated by mastication and other tooth contacts.
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Figure 1. Anatomy of the Periodontium Showing Gingiva, Periodontal Ligaments,
Cementum and Alveolar Bone.
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Risk Factors of Periodontitis
Many people who carry the periodontal pathogens in the oral cavity do not
manifest disease [18]. This important observation highlighted the role of patient
susceptibility together with the presence of specific periodontal pathogens in determining
the ultimate disease outcome. Added to this are environmental factors such as smoking
and stress.

Smoking
It is well accepted that smoking increases the risk for periodontal disease [19,20].
Nicotine, the major content in cigarette has been shown to be involved in osteoclast
mediated bone resorption. Nicotine was shown to increase secretion of IL-1, an
osteoclastogenic cytokine, in co-cultures of periodontal ligament (PDL) cells with
CD4+T cells [21]. Other studies have shown that nicotine can cause reduction in antiinflammatory and chemoattractant cytokines, which may be another possible mechanism
by which bacteria could survive in the gingival sulcus. Similar observation was made
when P. gingivalis stimulated dendritic cells showed altered function in the presence of
nicotine leading to reduction of proinflammatory cytokines [22,23]. Also, cigarette
smoke condensate, the particulate matter of cigarette smoke, which includes nicotine
among other chemicals, can increase the collagen-degrading ability of human gingival
fibroblasts by altering the production and localization of MMPs and TIMPs. Other
studies have associated suppression of B-cell function and immunoglobulin production to
cigarette smoking [24]. Finally there have been reports that associate smoking cessation
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with improved periodontal health [25]. Taken together cigarette smoking increases the
risk for periodontal disease.

Diabetes
Several reports have associated periodontal disease to diabetes [26,27].
Epidemiological data have confirmed that diabetes is a major risk factor for periodontitis,
in that susceptibility to periodontitis increased by approximately three fold in people with
diabetes [28]. Although mechanisms involved in this link is not clearly understood, it is
speculated to involve aspects of immune functioning, neutrophil activity and cytokine
biology. Emerging evidence support a two-way relationship between diabetes and
periodontitis, with diabetes increasing the risk for periodontitis, and periodontal
inflammation negatively affecting glycemic control [29]. Treatment of periodontal
disease results in reduction of HbA1C by approximately 0.4% [30]. These studies suggest
a comprehensive approach to management of diabetes in periodontal disease patients that
includes control of both diabetes and periodontitis.

Stress
Stress is known to affect normal functioning of the immune system and therefore
involved in various inflammatory diseases including periodontal disease. Mental stress
could also influence life-style and dental hygiene habits. This influence not only
decreases frequency and quality of dental hygiene but also leads to increase in the use of
tobacco, alcohol consumption and change in food habits leading to a diminution of the
general health [31,32]. Given that bacterial invasion is facilitated by poor oral hygiene
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and weaker immune response periodontal disease prevails. Moreover, stress is associated
with reduced saliva flow and change in composition (IgA) and pH of saliva [32,33]. In
gingival cervicular fluid stress has been shown to be a risk factor for gingival
inflammation with increase in interleukin-1b (an inflammatory cytokine) levels and the
presence of cortisol, which depresses the immune system [34-36]. People with aggressive
periodontitis were shown to be more depressed and socially isolated than with control
group, highlighting the relationship between aggressive periodontitis and psychosocial
stress [37,38]. These studies have clearly shown the two-way relationship exist between
periodontal disease and stress.

Genetics
The twin model, considered to be most powerful method to study genetic aspects
of any disease, have shown that between 38% and 82% of the population variance for
various measurements (attachment loss, pocket depth, gingival index and plaque index)
may be attributed to genetic factors [39]. This role of genetics and heritability in chronic
periodontitis has been well documented by other different studies [40-42]. However,
gene polymorphism in periodontitis has been the primary focus of most of the genetic
studies. Various genes have thus been implicated in the susceptibility to chronic
periodontitis (CP). For example polymorphism of the IL1 have been considered a risk
factor for chronic periodontitis for Caucasian CP patients [43], but the results were not
applicable for the worldwide population. Similarly various gene polymorphism including
polymorphism of IL1, IL6, IL10, VDR, and CD14 have shown some evidence of
association with chronic periodontitis susceptibility in certain population, but, the
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conclusion were not generalizable [44]. More research with stricter disease
classification, large study cohorts, adjusting for relevant risk factors in CP, and including
analysis of multiple genes and polymorphisms are needed to gain clarity of role of
genetics in periodontal disease.

Complications of Periodontitis
Various studies have associated periodontal disease with other systemic diseases
like cardiovascular disease (CVD), stroke, premature rupture of membrane and
respiratory disease. Periodontal disease (PD) is arguable the most common chronic
inflammatory disease known to man and inflammation is also the common factor for the
systemic disease associated with periodontal disease.

Cardiovascular Disease
Number of research supports moderate relative association between
cardiovascular disease (CVD) and periodontal disease assessed clinically and
radiographically [45,46]. Although most of these studies used epidemiological basis for
their conclusion newer studies have used novel approaches. Systemic antibody levels to
periodontal microbes have been evaluated and associated with increased prevalence of
coronary heart disease, increased atherosclerosis in the carotid artery and more risk of
developing coronary events during10 years of follow-up [47-49]. These studies also
correlated well with earlier epidemiological studies [50]. An even more direct approach
measured bacteria quantitatively in periodontal plaque for known periodontal pathogen
versus non-periodontal pathogen serving as controls [51,52]. The result showed that

10

carotid atherosclerosis as measured by intima-media thickening was increased with
higher levels of the periodontal bacteria [53]. In other interventional studies involving
small cohorts it was reported that periodontal treatment lead to improved measures of
systemic inflammation or subclinical CVD [54-56]. Two possible mechanisms are
proposed linking infection and periodontal disease to CVD. In the direct pathway oral
bacteria and their byproducts can gain systemic access via the circulatory system. Toward
this several studies have documented bacteremia associated with simple processes like
mastication to complex dental procedures like scaling [57,58]. Once gaining systemic
access, oral bacteria have the potential to directly influence subclinical mediators of
cardiovascular events such as hypercoagulability, atherosclerotic development or both. P.
gingivalis, the major agent in adult periodontitis, was demonstrated to accelerate
atherosclerotic development when administered intravenously and later its DNA was
recovered from the aortic tissue in an infected mice [59,60]. Moreover P. gingivalis was
able to, infect macrophages leading to formation of foam cells and aggregate platelets
increasing likelihood of thrombus formation, both leading to atherosclerotic process and
ischemic cardiovascular events [61-64]. On the other hand indirect pathways suggests
that the presence of periodontal pathogens leads to increased levels of systemic
inflammatory markers such as C-reactive protein, antibodies and heat shock proteins,
which in turn bring about vascular inflammation and atherosclerosis [65-67].

Preterm/Low Birth Weight Babies
Preterm/low birth weight is the most common adverse outcome of association
between pregnancy and periodontal disease. Some studies have used periodontal disease
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progression during pregnancy as predictor of more severe adverse pregnancy outcome of
very preterm birth, independent of other risk factors [68]. However, inconsistencies have
been reported of the efficacy of periodontal treatment on birth outcomes [69].
Preterm/low birth weight births may occur as a result of infection and is mediated
indirectly, principally by the translocation of bacterial products, such as endotoxin
(lipopolysaccharide), and the action of maternally produced inflammatory mediators.
Other studies have noted link a between in utero fetal exposures of oral pathogens to
increased neonatal intensive care unit admission and length of stay [70]. Infection with
bacteria are said to artificially increase the risk of biomolecules such as prostaglandin E2
(PGE2) and TNF-, which are normally involved in parturition, leading to premature
labor. Other studies have documented increased gingival inflammation, decrease in ratio
of peripheral T-helper cells to T-suppressor cells (CD4/CD8), decreased levels of
immunoglobulin G to periodontal pathogens during second trimester, ovarian hormone
stimulation of prostaglandin (PGE1 and PGE2), and influence of plasminogen activator
inhibitor type 2 (PAI2) disrupting the balance of the fibrinolytic system, all these leading
to suppressed immune system in the pregnant mother [70]. The rise in sex hormones
during pregnancy has direct effects on gingival tissue. While estrogen regulate cell
proliferation, differentiation and keratinization, progesterone influences permeability of
the microvasculature, alters rate and pattern of collagen production and, finally increases
the metabolic breakdown of folate which is crucial for fetal development. Therefore sex
hormones may exaggerate the periodontitis mediated effects on the developing fetus in a
feedback loop.
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Respiratory Infections
Anatomical proximity of the oral cavity to respiratory tract predisposed the
respiratory system to infection from oral flora. For example microbes that are normal
residents of the oropharynx usually cause community-acquired bacterial pneumonia and
other respiratory infections as these bacteria are aspirated into the normally sterile lower
respiratory tract [71]. This observation has been accepted as improved oral hygiene
resulted in reduction of nosocomial pneumonia in both ventilated an non ventilated
patients, linking respiratory infections to poor oral health of inpatients [72,73]. Such
cause-and-effect relationship has also been observed between periodontitis and COPD
further suggesting close link between poor oral hygiene and periodontal disease to
respiratory infections [74,75].

Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterized by inflammation of the synovial joints
that lead to swelling, stiffness, tenderness eventually leading to cartilage damage, bone
erosion and joint destruction. Autoimmunity is said to play major role its pathogenicity
leading to production of autoantibodies. Two antibodies namely rheumatoid factors,
antibody against self-IgG, and anti-citrullinated peptide antibody against common auto
antigens expressed within and outside joints are common features of patients with RA.
Link between periodontitis and RA have been made [76]. As with inflammatory
pathways as mechanism linking periodontal disease to other systemic diseases, so also is
inflammatory pathways thought to be the link between RA and periodontal disease
[77,78]. Also, presence in the synovial fluid of antibodies to Gram-negative, anaerobic
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periodontal pathogens, such as P. gingivalis, Prevotella intermedia and Tannerella
forsythia suggest their role in RA [79]. Moreover, these pathogens have been isolated
from synovial fluid cultures from patients with RA [80,81] and immunity to P. gingivalis
has been shown to be significantly associated the presence of RA-related autoantibody in
individuals at risk for RA [82]. Although there is little to support positive effect of
periodontal treatment on RA disease activity [83] there is some evidence to show that
periodontal infection and inflammation may hamper the effectiveness of anti-TNF
therapy in patients with RA [84,85].
In summary, surrogate markers for chronic periodontitis, such as tooth loss, show
relatively consistent but weak associations with multiple systemic conditions. Short-term
interventional trials have not supported this cause-and-effect relationship. However,
effective treatment of periodontal disease is necessary to achieve oral health goals, as
well as to reduce the risk of local chronic inflammation and bacteremia caused by these
periodontal pathogens.

Porphyromonas gingivalis and its Virulence Factors
P. gingivalis, a major pathogen causing adult periodontitis, is a Gram negative,
coccobacilli, which is anaerobic, asaccharolytic, fastidious and nonmotile. It forms black
colonies on BHI blood agar supplemented with vitamin K and hemin. This asaccharolytic
bacterium derives energy from metabolizing amino acids by producing potent proteases.
This is helpful, as they have to survive in deep periodontal pockets where there is no
supply of carbohydrates. As a late colonizer in the sub-gingival biofilm it is able to gain
access to gingival tissue [86,87]. The black pigmentation is said to be due to their ability
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to aggregate heme on its surface [88] as they lack any known siderophores with which
bacteria procure iron. We will now consider the virulence factors of P. gingivalis.

Fimbriae
The first step in establishing infection is contact with host tissue, in this case
gingival epithelial cell. P. gingivalis is able to accomplish this with the help of fimbriae.
Fimbriae are thin hairy cell protrusions that facilitate adherence to salivary proteins,
extracellular matrix, gingival epithelial cells and other bacteria. Initially fimbria helps
form biofilm by attaching to other bacteria. Two types of fimbria are reported, namely:
Type I (major) fimbriae or FimA, plays a role in colonization and invasion, and Type II
(minor) fimbriae Mfa, is said to have higher proinflammatory capacity [9,89]. Invasion
occurs when major fimbriae I bind to 1 integrin on the surface of host cells causing
rearrangement of actin cytoskeleton leading to internalization [90,91]. Fimbriaedependent proliferation of gingival epithelial cells ensues following internalization [92].
Interestingly two strains of P. gingivalis, W50 and W83 that lack major fimbriae are also
able to invade cells [93]. Fimbriae is associated with bone destruction in experimental
animal models [94]. Fimbriae are also known to elicit production of pro-inflammatory
cytokines (IL-1, IL-6, IL-8, TNF-) and matrix metalloproteinase MMP-9 [95-98]. TLR2
and TLR4 are the major receptors for the fimbriae mediated activation of host cells. The
TLR2 mediated signaling leads to two distinct pathways, one resulting in
proinflammatory cytokine production and the other leading to expression of cell adhesion
molecules, such as ICAM-1 [99]. On the other hand it is reported that signaling through
TLR4 requires additional co-stimulation of CD14 and MD-2 [100]. Also, major fimbriae
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were shown to exploit TLR2 signaling in order to interact with complement receptor 3
(CR3) thereby activating the binding capacity of CR3, which allows for internalization of
the bacteria in macrophages and reduction of IL-12. All this eventually leads to inhibition
of bacterial clearance [101,102].

Lipopolysaccharide
Lipopolysaccharide (LPS) is major component of Gram-negative bacteria that
help in pathogenicity. The affinity of LPS to pattern recognition receptors such as TLRs
and CD14 is well documented [103,104]. LPS has been shown to stimulate
proinflammatory cytokine production, such as IL-1, IL-1, IL-6, IL-8, IL-18 and TNF
in monocytes [105-108]. Although P. gingivalis LPS is a weak stimulator of cytokines
production when compared to LPS of enteropathogenic bacteria, it has the ability to
antagonize cytokine-stimulating capacity of other pathogens [106,107,109].
Structurally LPS of P. gingivalis is different from other species. While the lipid A
of most Gram-negative species is a strong activator of TLR4 response, P. gingivalis lipid
A is an activator of TLR2 and may even act as antagonist to TLR4 [99,110]. Based on
acylation lipid A of P. gingivalis is said to be of two varieties namely tetra-acylated and
the penta-acylated forms. The penta-acylated lipid A through TLR4 up regulates IL-6 and
IL-8 while the tetra-acylated which binds to TLR2 did not induce such significant host
response [110-112]. Also TNF- expression was promptly up regulated by the pentaacylated form and gradually declined afterward. Moreover, when hemin availability was
high, a condition reflecting inflammation, penta-acylated lipid A was converted to tetraacylated lipid A [113]. Therefore by modifying its lipid A structure according to the
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microenvironment, P. gingivalis may modulate the binding affinity of its LPS to its
cognate TLR receptors ultimately modulating inflammatory cytokine production, which
may help in its pathogenesis. Additionally a second type of LPS has also been reported
from P. gingivalis called anionic polysaccharide linked lipid A, A-LPS, shown to
involved in cell integrity, serum resistance and associated with Arg-X gingipain
[114,115]. Taken together P. gingivalis shows ability to manipulate its LPS to suit its
survival when inside the human host.

Capsule
As in every pathogenic bacterium another important virulence factor for P.
gingivalis is its capsule. Based on antibody response to capsular antigen six serotypes of
capsule have been reported [116,117]. The capsulated strains are more resistant to
phagocytosis by polymorphonuclear cells when compared to non-capsulated strains and
exhibited different capacity of adherence to gingival epithelial cells [118,119]. Cytokine
production was also different for the different serotypes when exposed to macrophage
and dendritic cells [120,121]. The role of capsule in downplaying the innate immune
response is supported by a study, which showed that a nonencapsulated knockout strain
was more potent inducer of cytokine response when compared to capsulated wild type
strain [122]. In murine lesion models, it was shown that capsulated strains were highly
invasive producing localized abscess [117]. However, newer studies using in-vitro
models could not come to the same conclusion suggesting confounding variables in this
study [123]. Further studies are required to conclusively associate capsule with invasive
capacity and deregulation of host response.
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Gingipains
Gingipains are cysteine protease produced by P. gingivalis, which used amino
acid metabolism for ATP production, and is found associated to the cell or secreted.
Eighty five percent of proteolytic activity of P. gingivalis is attributed to their ability to
produce gingipains [124]. Based on substrate specificity gingipains are classified into
arginine specific (Arg-X) and lysine-specific (Lys-X) gingipains [125,126]. Arg-X
gingipain is encoded by two genes rgpA and rgpB, while Lys-X gingipain is encoded by
kgp. RgpA and Kgp contain both proteolytic and adhesion domains while RgpB contains
only proteolytic domain [125]. Being powerful proteases the gingipains have been shown
to cleave several immune molecules, such as CD2, CD4 and CD8, leading to hamper
immune response. On the other hand they can stimulate expression of protease-activated
receptors in gingival epithelial cells, gingival fibroblast cells and T cells leading to
cytokine mediated chronic inflammation seen in periodontitis [127-130]. Gingipains can
modulate inflammation by controlling the production of inflammatory and antiinflammatory cytokines. Some studies have shown that they can stimulate production of
inflammatory cytokines like IL-6 and IL-8 thereby enhancing inflammatory response.
Others have shown that gingipains can inactivate both anti-inflammatory (IL-4, IL-5) and
pro-inflammatory (IL-12, IFN-) cytokines.
Gingipain can affect the complement system in many ways. It was shown that
gingipains destroy the bactericidal activity of human serum and can interfere with all
three pathways (classical, lectin and alternate) of complement system by degrading
several complement factors [131]. C5a, an anaphylotoxin, is a crucial component of the
complement system and mediates recruitment of PNMs leading to bacterial clearance.
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While Arg-X gingipains have been shown to cleave C5 resulting in the release of C5a,
Lys-X can inactivate C5a receptor on PNMs there by hindering their recruitment
[132,133]. Moreover, it is shown that Arg-X can degrade C3, another important
component of complement system [134]. C3b is involved in opsonization of bacterial
cells and degrading C3 could render the system incapable of opsonization leading to
increased resistance of P. gingivalis to bactericidal activity.
Gingipains also mediate other important functions like adherence and vascular
permeability leading to its survival in the human host. It has been shown that gingipains
can mediate bacterial attachment to host gingival epithelial cells and gingival fibroblasts.
Moreover, gingipain can also activate plasma kallikerin and bradykinin or alternatively
increase the release of thrombin and prothrombin, leading to increased vascular
permeability and PMN influx. Also, their ability to [135-137] degrade fibrinogen would
inhibit coagulation, which leads to increased bleeding at the site of infection. This is a
strategy profits P. gingivalis as it is now able to gain hemin, an important nutritional
requirement for survival. Further, gingipains have been shown to disrupt cell-cell and
cell-matrix adhesion and induce apoptosis. Recent studies have highlighted the role of
gingipain concentration gradient in modulating seemingly opposing functions of
inflammatory response. At high concentrations, near the biofilm, gingipains induce
apoptosis and attenuate the secretion of proinflammatory mediators, while at low
concentrations, deeper into the gingival connective tissue, they stimulate inflammation
leading to tissue connective tissue damage and alveolar bone loss, which are hallmarks of
periodontitis [138,139].
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Glycosylation
The completion of genome sequencing of various organisms has revealed that the
amount of genes could not account for the variations observed in the organism. Post
translational modifications (PTM) accounting for over 200 covalent modifications that
determine the biological, physical and chemical properties of proteins [140] is believed to
be involved in this variations observed. Examples of posttranslational modifications
include glycosylation, phosphorylation, sulfation, acetylation etc. Glycosylation is a
modification mediated by complex enzymatic machinery, by which glycans (sugars) are
covalently attached to specific amino acid sites of proteins, besides nucleic acid and
lipids. In eukaryotes, protein glycosylation occurs as they pass through the endoplasmic
reticulum and the Golgi complex. These glycosylated proteins are transported to cell
membrane or secreted from the cell. Glycosylation thus lead to formation of monomeric
and multimeric glycan linkages that are essential for cell viability, biochemical
communication and normal function. Glycosylation of proteins render important
properties where by proteins gain physiological functions like maturation, cell adhesion
and trafficking, receptor binding and activation. Dysfunctional glycosylation machinery
leads to pathogenesis in infectious diseases and development of chronic diseases like
cancer, neurological disorders and severe inflammation [141]. Unlike nucleic acids and
proteins, which are synthesized in a linear fashion based on template, glycan synthesis is
neither template based nor structurally linear. Branching is therefore common and
provides structural diversity.
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Glycosylation in Bacteria
It is now well accepted that glycosylation occurs in bacteria and that bacteria may
employ hitherto unknown pathways to glycosylate their proteins although classical N and
O–glycosylation have also been observed [142,143]. While in N-glycosylation glycans
are attached to amide nitrogen of Asn residues, in O-glycosylation the attachment is to
hydroxyl oxygen of Ser or Thr. It was found earlier that consensus sequence for Nglycosylation, Asn-X-Ser/Thr, observed in eukaryotes was also found in prokaryotes
[144]. However recent studies have shown that bacterial N-glycosylation sequence
contain an extended sequence containing Asp or Glu at the -2 position – Asp/Glu-X1Asn-X2-Ser/Thr, where X1 and X2 represent any amino acid except Pro [145]. Generally
N-glycosylation follow stepwise assembly of sugars (mediated by glycosyltransferases)
in the cytoplasm, donated by soluble nucleotide-activated sugars, to form an
oligosaccharide precursor attached via pyrophosphate to a lipid carrier called lipid linked
oligosaccharide (LLO). In bacterial LLO, the lipid is undecaprenol instead of dolichol
seen in eukarya and archaea. After assembly of the oligosaccharide, the LLO is flipped
from the cytoplasm to face the inner membrane. Finally the oligosaccharide is transferred
“en bloc” from the lipid carrier to the acceptor protein by the oligosaccharyltransferase
(N-OST) [146]. A common example is the LPS biosynthesis [147]. Interestingly,
Neisseria and Pseudomonas pilin glycosylation is said to have oligosaccharyltransferasemediated O-glycosylation pathways instead of the commonly found N-OST pathway
[148]. On the other hand O-glycosylation in bacteria has been shown to occur either by
sequential transfer or by block transfer, similar to N-glycosylation. In Campylobacter
jejuni O-glycosylation is reported in flagellin formation by sequential transfer of
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nucleotide-activated sugars to surface exposed Ser or Thr residues in the flagellin subunit
by glycosyltransferases (GTase) [143]. Interestingly in N. meningitides, the glycan are
assembled on the cytoplasmic side of the inner membrane on a lipid anchor by sequential
action of several Pgl proteins and flipped to the periplasm by PglF, where the
oligosaccharyltransferase (OTase) transfers the glycans to Ser/Thr residues of pilin
subunit PilE [143]. In addition, novels N-glycosylation mechanisms have been reported
from Haemophilus influenza, where the whole N-glycosylation process occurs in the
cytoplasm instead of the lipid anchor of the inner membrane [149].

Glycosyltransferases
Complex glycans play major roles in biology ranging from development of
embryo, function of immune system, microbial pathogenesis and cellular communication.
Among the various enzymes that take part in glycobiology of the cell,
glycosyltransferases (GTs) are the most important. GTs are enzymes that catalyze the
attachment of sugars from activated donors to an aglycone acceptor. Although most GTs
are specific for one monosaccharide that they transfer, exceptions are the
oligosaccharyltransferase that utilize large lipid linked oligosaccharide as mentioned
above. Functionally, GTs comprises one of the most diverse groups of enzyme, found in
all domains of life. There are about 87,000 GTs classified into about 91 families
according to their amino acid sequence similarities (CAZy database, CarbohydrateActive enZymes) [150]. In spite of the enormous dissimilarities observed in amino acid
sequences between GTs, structurally most of them belong to two superfamilies, namely
GT-A and GT-B, each consisting of two domains. Enzymes of GT-A fold have two
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dissimilar domains. The N-terminal contains several  sheets, which are each flanked by
-helices (Rossmann folds), which recognizes the sugar-nucleotide donor and, the Cterminal domain comprising largely of mixed -sheets containing the acceptor-binding
site. On the other hand GT-B fold contain two similar Rossmann-like folds. While the Nterminal domain provides the acceptor-binding site, the C-terminal domain is responsible
for binding the donor sugar. In both GT-A and GT-B fold, the two domains are connected
via a linker region and the active site is located between the two domains [150-152].

Chemistry of Glycosyltransferases
Glycosyltransferases exhibit different modes of action and require different
cofactors for its normal function. First, unlike GT-A, GT-B glycosyltransfeases are
metal-ion independent. Two common divalent cation cofactors are Mg++ and Mn++.
Secondly, most GTs are active at pH range of 5.0 to 7.0. Thirdly, GTs exhibit MichaelisMenten constants (Kms) for nucleotide sugar substrates in the low micromolar range
when assayed invitro. Although Km values for acceptor substrates determined by in vitro
studies vary dramatically for various enzymes (low micromolar to low millimolars), in
vitro studies are not likely to reflect circumstances found in subcellular compartments.
For this reason acceptor Km data of in vitro studies do not exactly represent actual
affinities for the natural substrates. Also other factors like site of production of GTs,
availability of sugar nucleotide-donors will affect glycosylation occurring in the cell.
Several glycosyltransferases act sequentially to bring about the final glycan
structure. Therefore every preceding and ensuing GTs is important for the glycosylation
to be complete. The end result is a linear and/or branched polymer composed of
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monosaccharide linked to one another. It was because of this precision by which each
GTs is able to catalyze its specific function in the presence different donors and acceptors
normally found in the cytoplasm, that the one-linkage-one-enzyme paradigm was
proposed. Several exceptions to this rule are now evident. Firstly, in members of the 2-8
sialyltransferases, it was found that specific glycosidic linkage might actually be the
product of one of several structurally and genetically related enzymes [153]. Secondly, as
in 1-3 fucosyltransferase, GTs and synthesize two different glycosidic linkages [154].
Thirdly, as seen in 1-4 galactosyltransferase, the presence of another protein (lactalbumin) could change the acceptor specificity from GlcNAc to Glc [155]. Finally, as
seen in proteoglycans, some GTs have been shown to catalyze two stepwise
glycosyltransferase reaction [141]. Additionally as many mammalian
glycosyltransferases have consensus N-glycosylation sequences, as well as serine and
threonine residues that can be glycosylated, some studies have shown that these sites are
indeed glycosylated. Therefore it is possible that GTs can themselves be glycoproteins.
Some have even suggested autoglycosylation of GTs [141].

Glycosyltransferase in P. gingivalis
As noted above glycosyltransferases in bacteria play a significant role in normal
physiology and specifically with pathogenic ability of bacteria. About twenty
glycosyltransferase are present in the genome of P. gingivalis W83 and most of them are
yet to be characterized. That glycosyltransferase mediated reactions are important for
virulence of P. gingivalis is highlighted by the fact that virulence factors like LPS,
capsular polysaccharide, fimbriae and gingipains are closely associated with
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glycosyltransferases, gtfB, PG0106, gtfB and vimF [156-159]. In the gtfB mutant there
was complete loss of surface-associated gingipain proteinases, autoaggregation and
biofilm formation due to defective O-LPS and A-LPS biosynthesis [157]. In the PG0106
mutant (which is closely related to vimF) involved in capsular biosynthesis it was noted
that there was an increase in auto-aggregation increased biofilm formation suggesting
surface variations leading to this phenotype [156]. In the gtfA mutant, the fimbriae was
not mature leading to decrease in auto aggregation and attachment to epithelial cells
suggesting role in pathogenicity by regulating adhesion [158]. Finally, similar
observations like reduced autoaggregation, increased biofilm formation, reduced
gingipain activity that were secreted, observed in the vimF mutant suggest their role in
pathogenicity [159].

Gingipain Maturation
To avoid untimed activation, gingipain like most proteases, are produced as
zymogens awaiting activation at a suitable time. Thus one of the key events in gingipain
maturation is the conversion of zymogen to the active enzyme. For RgpB it is shown that
three sequential autolytic processing steps at the N- and C-terminus are required for
gaining full activity. The first cleavage at Arg -103 was essential for the next two
processing at the N-terminal propeptide followed by one at C terminus [160]. Finally
after this post-translational modification two forms of RgpB, namely the low molecular
weight monomeric secreted RgpBcat and membrane bound RgpB, mt-RgpB, are made.
Processing of RgpA and Kgp are more complicated than that of RgpB. RgpA like RgpB
have an identical caspase-like catalytic domain (RgpAcat) and a membrane bound
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immunoglobulin like domain (mtRgpA) [161]. In addition RgpA also has C-terminal
extension containing hemagglutinin-adhesin domain. Kgp has the catalytic domain with
selectivity for Lys-Xaa peptide bonds followed by a C-terminal extension similar to
RgpA. RgpB lacks the hemagglutinin domains except for a short C-terminal domain,
which is similar to RgpA, Kgp and other secretory proteins [162,163]. If gingipain
activation requires autoproteolytic mechanisms, questions are raised on factors and
mechanisms that may be involved in this crucial process. From our lab we have
previously reported that genes of the vim locus are involved in this maturation/activation
process.

Gingipain Maturation and vim Locus
Genes of the vim locus include bcp, recA, vimA, vimE, vimF and aroG. In the wild type
P. gingivalis W83 mature gingipains were found to be active and mostly cell associated
with little secreted into the medium. This was altered in the vim defective mutants. In the
vimA mutant, gingipain activity was reduced by 90% in the exponential phase and 40% in
the stationary phase when compared to the wild type W83, and gingipains were mostly
found secreted into the medium [164,165]. Also it was shown that VimA could interact
with gingipains, RgpA, RgpB and Kgp[166]. Although glycan specific mAb 1B5
antibody did not immunoreact with surface polysaccharide and membrane-associated
Rgp gingipain, glycoprotein staining of these fractions was positive suggesting
incomplete glycosylation of surface and secreted proteins in the mutant [167]. Similar
observation was made in the vimE defective mutant also [168]. In addition, the
lipopolysaccharide profiles of the vimA and vimE mutants were truncated in comparison
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to that of W83. Further, VimA, in addition to its role in glycosylation and anchorage, is
shown to be involved in other virulence functions including oxidative stress resistance,
sialylation, acetyl coenzyme A transfer, protein sorting and transport [169]. In the vimF
defective mutant gingipain activities were reduced more than 90% and, in contrast to the
vimA mutant, the activity were unaffected by the growth phase. Moreover, nonactive
gingipain were found in extracellular protein fraction, with high-molecular-weight
proteins that immunoreacted with gingipain-specific antibodies. However, the
phosphorylated mannose specific mAb 1B5 antibody did not immunoreact with the
nonactive extracellular gingipains [159]. Other genes of the vim locus have been shown
not to be involved in gingipain maturation. While upstream genes bcp and recA have
been shown to play roles in oxidative stress resistance and DNA repair caused by UV
irradiation respectively, downstream gene aroG is thought to be involved in survival and
pathogenicity through synthesis of aromatic amino acids linked to lipid A biogenesis
[169-171]. Taken together it is clear that the vim genes are involved in the maturation of
gingipains and that they may be involved some way in glycosylation of gingipains and
that this step is crucial for anchorage of gingipains to cell surface.

Other Genes Involved in Gingipain Maturation
Apart from the genes of the vim locus, others, namely, porT, sov and gppX have
also been shown to be important for maturation of gingipains. While the Sec system is
said to transport gingipains across the inner membrane, the Por secretion system (PorSS)
has been shown to be involved in transporting various P. gingivalis proteins, including
gingipains, across the outer membrane, to the exterior. This system includes various Por
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proteins and the Sov gene product [172,173]. A common theme for the export of proteins
via the PorSS is the consensus CTD which has been found even in gingipain proteins
[162,163] although not unique to them [174]. PorSS is said to be a novel secretion system
and linked to gliding motility of the phylum Bacteroidetes [173]. Sov is shown to be an
outer membrane protein with the C-terminal region found exposed to the extracellular
milieu, involved in the modulation of Sov function.
The GppX was discovered when P. gingivalis W83 genome was surveyed for
homologues of FimS, a two-component sensor histidine kinase. Unlike FimR/FimS, the
most studied two component system (TCS) in P. gingivalis, GppX has both sensor and
response regulator domains in the same protein. Mutants of this gene exhibited
characteristic similar to vim mutants, in that they formed non-pigmented colonies and had
reduced gingipain activity that was mostly extracellular [175]. This protein is found to
regulate the post-translational maturation and localization of gingipains [175]. Also,
GppX is shown to negatively regulate expression of the luxS gene and can therefore be
involved in interspecies communication [176]. One of the orthologs of GppX from
Tannerella forsythia was shown to upregulate expression of glycosylation-related genes
modulating autoaggregation by post-translational modification of T. forsythia cell-surface
components [177].

Gingipain Glycosylation
Glycosylation of gingipain is suggested to be an important posttranslational
modification contributing to maturation/activation of gingipains adding them to the
growing list of bacterial glycoproteins. Biochemical analysis of Rgps have revealed that
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the monomeric enzymes are glycoproteins containing between 14% (RgpAcat and RgpB)
and 30% (mt-RgpAcat and mt-RgpB) carbohydrate by weight [114]. Monosaccharide
composition of RgpA revealed the presence of at least nine different sugars – Arabinose,
Rhamanose, Fucose, Manose, Galactose, Glucose, N-acetylgalactosamine, Nacetylglucosamine, and Sialic acid [178]. In a seminal paper Curtis and colleagues
demonstrated that gingipains are post translationally modified with carbohydrate
additions that are cross-reactive with monoclonal antibody 1B5 [114,179]. This antibody
raised against monomeric RgpA reacted with P. gingivalis LPS and membrane-associated
forms of RgpA and RgpB, and not with heterodimeric HRgpA and soluble forms of
RgpB. Chemical deglycosylation of gingipains abolished this immunoreactivity,
suggesting the role of glycosylation in maturation of gingipains. Also dephosphorylation
of anionic polysaccharide abolished cross reactivity to mAb 1B5. Taken together this
phosphorylated branched mannan could be a part of the glycan present on Arg-gingipains
that is immuno-reactive to mAb 1B5 [115]. Using this antibody, reports from our lab
have linked the Vim proteins to secretion, processing leading to maturation of gingipains.
Although glycosylated proteins were detected in the membrane and extracellular fractions
from vimA and vimE defective mutants, they failed to react with mAb 1B5 antibody[167].
Also, in the vimF defective mutant, polysaccharide profile appears to be similar to that of
the wild type, however 1B5 antibody did not react with the membrane preparations,
suggesting carbohydrate modifications [159].

C-terminal Residues of RgpB and Maturation
Various studies have associated the role of C-terminal residue of gingipains in
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glycosylation, leading to anchorage to the cell membrane and maturation of gingpains
[163,180,181]. Truncation of the last two residues (Valyl-lysine) from C terminus of
RgpB, is shown to create an inactive version of the protein that lacks post-translational
glycosylation and protein trapped behind the outer membrane [162]. Recently it was
shown that residues 692 to 702 of the C-terminal domain of RgpB play an important role
in attachment to cell surface [180]. While the role of C-terminal domains in these
functions is becoming clearer, there are not enough studies to ascertain the genes
involved in glycosylation of gingipains. In one study it was shown that expression of
RgpB is itself required for proper glycosylation of monomeric RgpA [178]. Moreover,
gene products of wpbB and several gene of porR locus have been shown to be involved in
maturation of gingiapns [179,182]. Although these genes are known to be involved in the
synthesis of O-antigen side chains of LPS, isogenic mutants showed characteristic loss of
pigmentation, glycan synthesis and glycosylation, with reduced gingipain activity that
was mostly soluble, observed by us in the vim mutants. Although the vimA-defective
mutant displayed a similar phenotype as the porR mutant, the gingipains in the vimE and
vimF mutants were cell associated and inactive. In addition, unlike vimA mutant, late
onset of gingipain activity was not observed in vimE and vimF mutants suggesting other
modifications beyond those that facilitate membrane anchorage are needed for activation.
vimF is annotated as a putative glycosyltransferase and its inactivation resulted in
decrease of both lysine-specific and arginine-specific gingipain activity with multiple
high molecular weight protein found in the extracellular fraction, which were irrelevant
of their growth phase.
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Approach of the Study
The work of this thesis focuses on VimF mediated glycosylation of gingipain in
P. gingivalis, more specifically, this work was started aiming to determine
glycosyltransferase function of this protein and to understand the site where this putative
glycosyltransferase is able to accomplish its biological function. In the second chapter we
focus on the ability of VimF to function as a galactosyltransferase and show its ability to
transfer galactose to pro-gingipain species. In addition, this chapter also documents VimF
mediated phenotypic changes brought about in two genetic backgrounds namely, W83
and ATCC 33277. Further, questions are raised regarding the glycosylation status of
VimF protein. The third chapter will focus on site where this VimF mediated
glycosylation takes place. Attempts that were made to localize VimF within the bacteria
will be documented. The fourth chapter will be an over all summary of the impact of this
study in understanding the molecular aspects of VimF mediated gingipain maturation.
Here important outcomes of this study will be brought out in light of biology of this
protein and various ways to target this protein for treatment options will be highlighted.
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Abstract
Previously, we have reported that gingipain activity in Porphyromonas gingivalis,
the major causative agent in adult periodontitis, is post-translationally regulated by the
unique Vim proteins including VimF, a putative glycosyltransferase. To further
characterize VimF, an isogenic mutant defective in this gene in a different P. gingivalis
genetic background was evaluated. In addition, the recombinant VimF protein was used
to further confirm its glycosyltransferase function. The vimF-defective mutant (FLL476)
in the P. gingivalis ATCC 33277 genetic background showed a phenotype similar to that
of the vimF-defective mutant (FLL95) in the P. gingivalis W83 genetic background.
While hemagglutination was not detected and autoaggregation was reduced, biofilm
formation was increased in FLL476. HeLa cells incubated with P. gingivalis FLL95 and
FLL476 showed a 45% decrease in their invasive capacity. Antibodies raised against the
recombinant VimF protein in immunoreacted only with the deglycosylated native VimF
protein from P. gingivalis. In vitro glycosyltransferase activity for rVimF was observed
using UDP-galactose and N-acetylglucosamine as donor and acceptor substrates,
respectively. In the presence of rVimF and UDP-galactose, a 60 kDa protein from the
extracellular fraction of FLL95 which was identified by mass spectrometry as Rgp
gingipain, immunoreacted with the glycan specific mAb 1B5 antibody. Taken together,
these results suggest the VimF glycoprotein is a galactosyltransferase that may be
specific for gingipain glycosylation. Moreover, galatose is vital for the growing glycan
chain.
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Introduction
Porphyromonas gingivalis, a Gram-negative, anaerobic bacterium, is a major
etiological agent implicated in adult periodontal disease and is associated with other
systemic diseases, including cardiovascular disease [1–5]. This data, taken together,
implies a significant impact of this organism on the overall health of humans. The ability
of this asaccharolytic bacterium to produce proteases has been shown to contribute
significantly toward its pathogenicity [6]. A key element in modulating the pathogenic
potential of P. gingivalis is the post-translational modification of the major proteases,
called gingipains [7]. These consist of arginine-specific (Arg-gingipain [Rgp]) and
lysine-specific (Lys-gingipain [Kgp]) cysteine proteases that are both extracellular and
cell membrane associated [8]. The maturation pathway of the gingipains including its
secretion facilitated by a novel POR secretion system (PorSS) is linked to carbohydrate
biosynthesis. This pathway is regulated by several proteins including the PorR, PorT,
Sov, Rfa, VimA, VimE, VimF and other components of PorSS [Reviewed in [9–11]].
However, there still remains a gap in our comprehensive understanding of the
glycosylation process important in gingipain biogenesis. More specifically, the role of
VimF in this process is still unclear.
The bcp-recA-vimA-vimE-vimF-aroG operon is essential for the
maturation/activation/anchorage of the gingipains and regulation of other virulence
factors of P. gingivalis [10]. Previously, we have reported that the vimF gene can affect
the phenotypic expression and distribution of the gingipains in P. gingivalis [12]. Using
the cloned vimF gene, a defective mutant was constructed by allelic exchange in W83.
This isogenic mutant designated P. gingivalis FLL95, when plated on Brucella blood agar
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was non-pigmented and non-hemolytic. In contrast to the parent strain, arginine- and
lysine-specific gingipain activities were reduced by approximately 97% and 96%,
respectively. These activities were unaffected by the growth phase in contrast to the
vimA-defective mutant P. gingivalis FLL92. Expression of the rgpA, rgpB and kgp
gingipain genes were unaffected in P. gingivalis FLL95 when compared to the wild-type
strain. In non-active gingipain extracellular protein fractions, multiple high molecular
weight proteins immunoreacted with gingipain specific antibodies. However, the specific
phosphorylated mannan oligosaccharide moiety recognized by the monoclonal antibody
1B5 [13] was absent in gingipains from FLL95. Taken together, these results suggest that
the VimF protein which is a putative glycosyltransferase group 1 is involved in the
regulation of gingipain biogenesis in P. gingivalis through glycosylation.
Glycosyltransferases (GTases) catalyze the transfer of monosaccharide or
oligosaccharides primarily from an activated sugar donor (UDP sugars) to various
substrates, including carbohydrates, proteins and glycoproteins [14]. Their physiologic
significance is further highlighted by the fact that they, along with glycosidases, make up
1 to 2 % of the encoded genes in living organisms [15]. Recently, various reports have
associated glycosyltransferases with the biogenesis of several virulence components of P.
gingivalis like capsule [16], fimbriae [17], lipopolysaccharide [18] and gingipains [12].
The carbohydrate composition of the gingipains which is estimated to be 14% to 30% by
weight underscores the importance of glycosylation in their maturation process [13].
The post-translational addition of carbohydrates to the gingipains is highly
variable, thus implying a role for multiple factors in this process [11,13]. The attachment
of carbohydrates to proteins can be either N- and/or O-linked. The N-linked attachment is
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to the amide nitrogen of asparagine facilitated by a consensus amino acid sequence of
Asn-X-Ser/Thr (N-X-S/T), where X is any amino acid except proline [19]. The Oglycosidic linkage occurs via glycan attachment to the hydroxyl group of serine (S), or
threonine (T) [19]. These attachments of sugar to the amino acid chain and glycans on
glycoproteins are both mediated by glycosyltransferses. While several GTases are present
in the genome of P. gingivalis [20] their specific effect on gingipain maturation is less
clear. In this report, we have further characterized the putative glycosyltransferase VimF
and demonstrated its ability as a galactosyltransferase involved in glycosylation of the
pro-gingipain species in P. gingivalis.

Materials and Methods
Bacterial Growth Conditions and Gingipain Assays
All strains of P. gingivalis were grown in brain heart infusion (BHI) broth (Difco
Laboratories, Detroit, MI) supplemented with hemin (5 µg/ml), vitamin K (0.5 µg/ml)
and cysteine (0.1%). Defibrinated sheep blood (5%) and agar (10%) were used in blood
agar plates. Escherichia coli strains were grown in Luria-Bertani (LB) broth. Unless
otherwise stated, all cultures were incubated at 37oC. P. gingivalis strains were
maintained in an anaerobic chamber (Coy Manufacturing, Ann Arbor, MI) in 10% H2,
10% CO2, and 80% N2. Growth rates for P. gingivalis and strains were determined
spectrophotometrically (optical density at 600 nm [OD600]). Antibiotics were used at the
following concentrations: clindamycin, 0.5 µg/ml; erythromycin, 300 µg/ml; and
carbenicillin, 50 to 100 µg/ml. Rgp and Kgp activities were determined using the
microplate reader (Bio-Rad Laboratories, Hercules, CA) as previously reported [21].
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DNA Isolation, Analysis and Cloning of the vimF Gene.
Chromosomal DNA was extracted from P. gingivalis W83, 33277 and isogenic
mutants (Table 2.1) as previously described [22]. Alkaline lysis method was used for
plasmid DNA extraction [23]. Electrophoresis of DNA was done using 0.8% agarose gel
prepared in TAE buffer as reported elsewhere [12]. The pTrcHis2-TOPO TA expression
vector (Invitrogen, Carlsbad, CA) was used for generating the rVimF protein. Briefly, the
1.2-kb vimF open reading frame without stop codon was amplified from P. gingivalis
W83 chromosomal DNA using P1 and P2 oligonucleotide primers (Table 2.2). The
amplified fragment was purified using the QIAquick PCR Purification kit (Qiagen,
Valencia, CA) then cloned into the pTrcHis2 plasmid vector following the
manufacturer’s protocol. This recombinant plasmid was then used to transform Top 10
competent cells that were then plated on LB agar containing 50 µg/ml of ampicillin.
Recombinant plasmids, named pFLL477 (Table 2.1), isolated from several ampicillin
resistant colonies were screened for the correct orientation of the insert using PCR and
confirmed by digestion with KpnI and SphI. One randomly chosen ampicillin resistant
transformant carrying the recombinant plasmid pFLL477 was chosen for further studies.
DNA sequencing was used to confirm the absence of any mutation in the vimF ORF.

Purification of rVimF
An overnight culture of the Top 10 cells carrying pFLL477 was used to inoculate
two liters of prewarmed LB broth containing 50 µg/ml ampicillin. The culture was then
grown at 37oC to the exponential phase (OD600 = 0.6) after which it was induced with
1mM IPTG and further incubated for 5 hours. The cells were harvested by centrifugation
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(2,400 g for 20 minutes) and washed twice with 10 mM Tris-HCl at pH 7.4. The cell
pellet was suspended in binding buffer (20 mM NaH2PO4, 500 mM NaCl and 40 mM
Imidazole) and frozen at -20oC. The cells were thawed and lysed by French pressure cell
press with five passes in the presence of Mini EDTA-free protease inhibitor tablets
(Roche, Indianapolis, IN) after the first and the last passes. After centrifuging the lysate
at 2,400 g for 20 minutes to remove cell debris, the cleared supernatant was further
centrifuged at 100,000 g for 1 h. The resultant supernatant was either stored at -80OC and
used in a glycosyltransferase assay or, mixed with 1 liter of binding buffer containing
0.5% tween and loaded on to the His-Prep FF 16/10 column (GE Healthcare, Piscataway,
NJ) for protein purification. After washing the column twice with two column volumes of
wash buffer (same as binding buffer), the bound proteins were eluted with buffer
containing 500 mM imidazole, 20 mM NaH2PO4 and 500 mM NaCl. Fractions
containing the 50 kDa proteins were pooled, buffer exchanged with 10 mM Tris-HCl (pH
7.4) using 10,000 MW cutoff membrane in an ultrafiltration cell (Amicon Inc., Beverly,
MA) and concentrated using a speed vacuum concentrator (Savant Instrument, Inc.,
Farmingdale, NY).

Production of Rabbit Polyclonal Antibodies Against the rVimF Protein
To avoid the 60 kDa GroEL band that was observed to co-purify with rVimF, the
purified rVimF (25 µg/lane) was separated by SDS-PAGE using NuPAGE 4 to 12% BisTris gels and excised for antibody production. A total of approximately 1.2 mg of the
rVimF protein was excised from the gels, placed in 1x PBS buffer, and sent to Open
Biosystems Inc., Huntsville, AL., for the production of polyclonal rabbit VimF antibodies
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by using the manufacturer's standard protocol. Dilutions and efficiency of the antibodies
were tested in the laboratory with the purified rVimF. All serum was aliquoted and stored
at -80oC.

Preparation of P. gingivalis Total Cell and Cell-Free Supernatant
Fractions
Total cell lysate and extracellular fractions were collected from P. gingivalis W83
and FLL95. Cells were grown to log phase and centrifuged at 10,000g for 30 minutes at
4oC. The proteins from the cell-free supernatant were precipitated with ammonium
sulphate (80%). The protein pellet was re-suspended in 10 mM Tris-HCl (pH 7.4) and
dialyzed extensively against the same buffer to remove ammonium sulphate. The cell
pellet was washed two times with 10 mM Tris-HCl (pH 7.4) and kept at -20oC. The cells
were lysed by French Pressure Cell Press (American Instrument Company, Silver Spring,
MD) as previously described [12]. Following centrifugation for 10,000 g for 30 minutes
to remove cell debris, the supernatant was designated as the total cell lysate.

Purification of Gingipain Protease
The gingipains were purified as previously reported [24] with some
modifications. Ammonium sulfate instead of acetone precipitation was used to precipitate
the gingipains from the culture supernatant of P. gingivalis FLL95 or W83 grown to
OD600 of 0.8-1.0. In addition, four columns were used in the following order: Hi Load
16/60 Superdex 200 (GE Healthcare, Piscataway, NJ), DEAE Sepharose FF XK16 anion
exchange column (Amersham Bioscience, Piscataway, NJ), Arginine Sepharose column
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(GE Healthcare, Piscataway, NJ), followed by the Superdex 200HR 10/30 column
(Amersham Bioscience, Piscataway, NJ).

SDS-PAGE and Western Blotting
10% SDS-PAGE gel was used for protein separation of purified rVimF and cell
lysates of E.coli and P. gingivalis strains. Samples were mixed with approximately 10%
NuPAGE reducing agent and 25% 4X LDS buffer and heated for 10 minutes at 72oC.
Electrophoresis was done at 130V for 70 minutes and stained with SimplyBlue SafeStain
for visualization. Nitrocellulose membrane with pore size 0.45 µm (Schleicher & Schuell,
Reviera Beach. FL) was used for blotting using 15 V for 25 min in a Semi-Dry Trans-blot
apparatus (Bio-Rad, Hercules, CA). These blots were probed by using either rabbit antirVimF antibody (1 in 4000 dilution) or, mouse mAb IB5 (1 in 20 dilution) demonstrated
to immunoreact with gingipain-associated sugar moiety [13]. Primary antibody was
allowed to react with the membrane for 1 hour and, following 4 washing steps, secondary
antibody (HRP conjugated goat anti-rabbit or goat anti-mouse, both in 1 in 4000 dilution)
was allowed to react for 30 minutes. Following 2 more washing steps, immunoreactive
proteins were detected by the procedure described in the Western Lightning
Chemiluminescence Reagent Plus kit (Perkin-Elmer Life Sciences, Boston, MA).

Glycosyltransferase Assay
Calibration Curve
A calibration curve, as previously described [25], was generated to establish the
relationship between proton production and change in absorbance of the pH indicator.
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The reaction mixture (1 ml final volume) contained 2 mM sodium phosphate buffer (pH
8), 0.01 mM phenol red, 0.1 mM MnCl2, 10 mM N- acetylglucosamine, 100 µl of Top
10 cells expressing pFLL477 lysate and different volumes of HCl (10 mM) was added to
get final concentrations of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 mM. The absorbance of
the mixture was determined spectrophotometrically (optical density at 557 nm [OD557]).
The data points were plotted using GraphPad Prizm 5 software (La Jolla, CA).
To screen for donor and acceptor substrate, 2 mM phosphate buffer (pH 8)
containing 0.1 mM phenol red, 0.1 mM MnCl2, 10 mM N-acetylglucosamine (acceptor),
100 µl of crude lysate of Top 10 cells containing pFLL477 and UDP-sugars (galactose or
glucose) were added to a final concentration of 2 mM. The absorbance at 557 nm was
monitored for each sample at 15s intervals for a total of 60 minutes using the
spectrophotometer Beckman DU 650(Beckman Coulter, Brea, CA). Other acceptor
substrates used in place of N-acetylglucosamine were – glucose, galactose, lactose, Nacetylgalactosamine and mannose. All reactions were carried out at a constant
temperature of 37oC. Enzyme activity was calculated using the GraphPad Prizm 5
enzyme kinetics option by intrapolating the OD557 values from calibration curve. A
commercially available bovine β-1, 4 galactosyltransferase (Sigma, St. Louis, MO) was
used as positive control and a non-specific Top 10 cell lysate served as negative control.
All enzymatic assays were done in triplicate and values averaged.

P. gingivalis Proteins as GTase Acceptor Substrate
Extracellular and whole cell lysates of W83 and FLL95 were used as acceptors in
the in-vitro Galactosyl transferase assay [25] in the presence of UDP-galactose (donor).
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Briefly, in a total reaction volume of 16 µl, supernatant containing about 7 to 15 µg of P.
gingivalis extracellular protein (in 10 mM Tris-HCl) was mixed with 5 µg of lysate
(containing pFLL477 producing the rVimF protein) and 1 µl of 0.8 mM UDP-galactose.
This mixture was incubated at 37oC for 2 hours. Similar reactions omitting rVimF lysate
and/or UDP-galactose served as controls. After incubation, the reaction was stopped by
adding 4X lithium dodecyl sulphate (LDS) buffer (Invitrogen, Carlsbad, CA), reducing
agent and water to make up a final volume of 20 µl. The samples were denatured at 72oC
for 10 minutes then separated on 10% SDS-PAGE at 130 V for 70 minutes. Carbohydrate
specific modifications were visualized using the glycan specific mAb 1B5 antibody in
western blot analysis as described elsewhere [13].

Glycoprotein Staining of rVimF and Gingipains
Purified rVimF along with positive and negative controls provided in the
Glycoprotein Staining Kit (Pierce, Rockford, IL) were separated by SDS-PAGE and then
transferred to nitrocellulose membrane and stained as per manufacturer’s instructions.
The membrane was stored in deionized water. Glycoproteins were seen as magenta bands
with light pink or colorless background. For glycoprotein staining of gingipains,
equivalent amounts of purified proteins (W83 catalytic domain and FLL95 proenzyme)
were resolved on a 10% separating gel using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in MOPS (Morpholinepropanesulfonic acid)-SDS running
buffer according to manufacturer’s instructions. Glycoprotein stain was then performed
on the gel using Pierce Glycoprotein Staining Kit as per manufacturer’s instructions. An
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equivalent gel was stained using SimplyBlue SafeStain (Invitrogen, Carlsbad, CA) for
comparison.

Determination of Glycosyl Composition of Proenzyme from FLL95
Protein samples (100 µg) were dried and the monosaccharide composition of the
proenzyme from FLL95 was determined by methanolysis and silylation followed by GCMS analysis of trimethylsilyl (TMS)-methyl glycosides [26], with the addition of a
reacetylation step just prior to silylation using 25 µl of methanol, 25 µl of pyridine, and
25 µl of acetic anhydride at room temperature for 15 minutes, in order to detect amino
sugars.

Tryptic Digestion and Mass Spectroscopy
SDS-PAGE separated protein bands and spots from 2D gels were excised and
subjected to digestion with trypsin. The gel slices were first transferred to low retention
epi vials (Fisher, Hampton, NH) and dehydrated using neat acetonitrile for 30 minutes. 20
µl of TCEP (tris(2-carboxyethyl)phosphine) was then added and incubated for 1 hr. at
60oC. In the next step, 40 µl alkylating buffer (200 mM iodoacetamide) was added and
incubated at room temperature for one hour. The gel slice was washed in 0.5 ml of neat
acetonitrile and re-suspended in another 0.5 ml of neat acetonitrile to dehydrate. Next,
digestion buffer containing mass spectroscopy grade trypsin in 50 mM NH4HCO3 was
added to attain a 1:20 to 1:50 enzyme/substrate ratio and incubated overnight at 40oC.
Digestion was stopped using 10 µl of 10% formic acid. Digested peptides were extracted
using standard C18 Zip Tip technology (Millipore, Bedford, MA) according to
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manufacturer’s protocol. MS analysis of extracted peptide was done as described
elsewhere [27].

Inactivation of the vimF Gene in P. gingivalis ATCC 33277
Fusion PCR, used successfully to inactivate genes in our lab [28,29], was used to
inactivate the vimF gene in 33277. Briefly, a 1 Kb region upstream of vimF was
amplified with a 5’ overhang that was complementary to a 3’ region of ermF using
primers P3 and P4 (Table 2.2) and, 1Kb downstream of vimF was amplified with 3’
overhang complementary to 5’ end of ermF by using primers P5 and P6 (Table 2.2).
ermF was amplified separately using primer P7 and P8 (Table 2.2). Finally, the purified
upstream, downstream and ermF fragments were combined in one PCR reaction using
primer P3 and P6 to replace vimF by ermF by PCR. The fused fragment was purified and
electroporated into P. gingivalis 33277 cells. The electrotransformed cells were plated on
BHI blood agar plate containing 10 µg/ml of erythromycin and incubated for 8 – 10 days.
Non-black pigmented colonies on blood agar were screened for the correct gene
replacement by PCR and DNA sequencing. One isogenic mutant randomly chosen and
designated FLL476 (33277ΔvimF) was used for further studies.

Complementation of vimF Mutants
PCR mediated gene replacement was used to complement the vimF defective
mutants. Briefly, using primers P9 and P10 (Table 2.2) the ORF of vimF with 500 bp
flanking regions of both upstream and downstream was first amplified from P. gingivalis
W83 and 33277 chromosomal DNA and purified using the QIAEX Gel Extraction Kit
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(Qiagen, Valencia, CA). This purified fragment was electroporated into P. gingivalis
FLL95 or FLL476 cells grown to exponential phase (OD600=0.6). Electroporated cells
were incubated for 12 hours in 1 ml of BHI broth then plated on BHI blood agar plates.
Plates were then screened after 8 days for black pigmented colonies. These colonies were
subsequently checked for the presence of the uninterrupted vimF gene. One randomly
chosen colony designated P. gingivalis FLL95C’ or FLL476C’ was chosen for further
study.

Autoaggregation, Hemagglutination and Biofilm assays
Autoaggregation assays of P. gingivalis ATCC 33277 and FLL476 was
performed as previously described [30] with slight modification. Briefly, P. gingivalis
cells in the early to mid-log phase was collected by centrifugation, washed three times
with PBS, and then re-suspended in PBS to an OD600 of 1.0. Autoaggregation was
monitored by the decrease in OD600 of each suspension over a three hour period at 37oC.
Hemagglutination activity was determined as previously reported [31]. After
serially diluting the bacterial suspension in a round bottom 96-well microtiter plates an
equal volume of (100 µl) of 1% PBS washed sheep erythrocytes was mixed with each
dilution and incubated at 4oC for 3 h. Hemagglutination was visually assessed and the last
dilution showing complete hemagglutination was taken as the titer.
Biofilm formation was estimated as previously described [32] with little
modification. Briefly, P. gingivalis cells grown overnight was washed twice with 1X PBS
buffer and re-suspended in BHI-PBS (ratio 1:2) at OD600 of 0.2-0.3. 100 µl of this cell
suspension was added to multiple wells of a pre-sterilized 96 well plate, covered and
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incubated overnight at 37oC anaerobically. Next day, free floating cells were aspirated
and wells were washed four times with 100 µl of 1X PBS. After drying the plates at 37oC
for 30 minutes, 100 µl of 0.5% (w/v) crystal violet was added to the wells and incubated
for 30 minutes at room temperature. After removing the crystal violet solution, the wells
were washed four times with 1X PBS and de-stained using 100 µl of 95% ethanol for 30
minutes. The released crystal violet was collected in a cuvette and after adding 500 µl of
ddH2O the biofilm formation was measured for each well at OD595.

Electron Microscopic Analysis
Tecnai G2 20 Transmission Electron Microscope was used as previously reported
[33], to visualize the surface structure of wild type P. gingivalis W83 and ATCC 33277
strains compared with their corresponding respective isogenic mutants FLL95 and
FLL476, respectively. Briefly, Formvar-carbon coated grids were prepared; the Formvar
support was removed by placing the grids in an atmosphere of solvent vapor. Grids were
then placed on a wire mesh in a glass Petri dish, with carbon tetrachloride below the wire
mesh. Cultures at OD600 =0.8 was pre-clarified and washed twice with PBS (pH 7.2).
The final pellet was dissolved in PBS to get OD600 of 0.7. About 200 µl of the processed
sample was loaded into a 500 mesh. The grids were then washed in 0.5% acetic acid then
by acetone. The carbon film was broken to free the specimen grid, after which the grid
was placed in stain solution - neutral 1% aqueous phosphotungstic acid for 30 seconds.
After blotting dry, the grid was examined using the Tecnai G2 20 Transmission Electron
Microscope.
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Adherence and Antibiotic Protection Assay
The HeLa cells were grown and maintained in the Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), streptomycin
(100 IU/ml), and amphotericin B (2.5 mg/ml) (Invitrogen, Carlsbad, CA), at 37oC under
5% CO2 atmosphere. Confluent stock cultures were trypsinized, adjusted to
approximately 5 x 103 cells/ml, seeded into 12-well plates (Nunc, Rochester, NY) 1 ml
per well and further incubated for 48 h to reach semi-confluency (105 cells per well).
Standard antibiotic protection assay was used to quantify invasion [34]. Briefly, an
isolated colony harvested from solid agar plate was grown to exponential phase in BHI
broth. The cells were centrifuged, washed three times in 1 X PBS, and adjusted to 107
CFU/ml of bacteria (confirmed by colony count) in Dulbecco’s modified Eagle’s
medium. Epithelial cell monolayers were washed three times with PBS, infected with
bacteria at a multiplicity of infection (MOI) of 1:100 (105 epithelial cells), and then
incubated at 37oC for 90 min under a 5% CO2 atmosphere. Non-adherent bacteria were
removed by washing with PBS, while cell surface bound bacteria would be killed with
metronidazole (200 µg/ml, 60 min). P. gingivalis in general is sensitive to 100 µg/ml
metronidazole. After removal of antibiotic, the internalized bacteria were released by
osmotic lysis in sterile distilled water with scraping. Lysates were serially diluted, plated
(in duplicate) on BHI agar, and incubated for 6 to 10 days. The number of bacterial cells
recovered was expressed as percentage of the original inoculum. The number of adherent
bacteria was obtained by subtracting the number of intracellular bacteria from the total
number of bacteria obtained in the absence of metronidazole.
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Results
VimF Defective Mutant Displays a Similar Phenotype in a Different
Genetic Background of P. gingivalis
Inactivation of the vimF gene in P. gingivalis W83 resulted in a non-black
pigmented isogenic mutant designated P. gingivalis FLL95, which showed reduced levels
of proteolytic, hemagglutinating and hemolytic activities [12]. To further confirm this
phenotype in a different genetic background, a vimF deletion mutant in P. gingivalis
ATCC 33277 was constructed by allelic exchange mutagenesis. Following
electroporation and plating on selective medium, several erythromycin-resistant colonies
were detected after 5 -7 days of incubation. To compare their phenotypic properties with
those of the wild-type 33277 strain, all mutants were plated on Brucella blood agar plates.
In contrast to the wild-type, all the isogenic mutants had a non-black pigmented, nonhemolytic phenotype. PCR amplification of chromosomal DNA showed that the vimF
gene was missing in those isogenic mutants in comparison to the wild-type. One
randomly chosen mutant, designated FLL476, was chosen for further characterization.
The mutation was further confirmed by DNA sequencing (data not shown). Because of
the use of an ermF cassette lacking a transcriptional terminator, inactivation of vimF did
not have any polar effects on the expression of its downstream genes which was
confirmed using PCR analysis (data not shown). In FLL476 the growth rate (Fig. 2.1A)
and gingipain activity (Fig. 2.1B) were reduced to similar levels as previously observed
in P. gingivalis FLL95 [12]. Complementation of FLL95 and FLL476 with the wildtype gene, which was confirmed using RT-PCR (data not shown), restored growth rate
and gingipain activity to both W83 (Fig. 2.1C and D) and ATCC 33277 (Fig. 2.1A and B)
wild type levels.
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D
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Figure 2.1. Comparison of growth and gingipain activities of wild-type, vimF mutant and
complemented strains of W83 and ATCC 33277. Growth rate of P. gingivalis W83 (A) and ATCC
33277 (C) were compared with their respective vimF-defective isogenic mutants (FLL95 and FLL476)
and complemented strains (FLL95C’ and FLL476C’). The data shown is an average of three
independent replicates. Error bars represent the SD. Gingipain activity of W83 (B) and ATCC 33277
(D) were compared with respective mutants and complemented strains. The activities were normalized
to W83 and ATCC 33277 being 100% and the mutants reported as a percentage thereof. Error bars
represent SD.
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VimF can Modulate Biofilm Formation, Autoaggregation and
Hemagglutination in P. gingivalis ATCC 33277
Alteration in P. gingivalis cell surface could alter their ability to autoaggregate,
hemagglutinate and form biofilm [35–37]. To ascertain the involvement of vimF in cell
surface modification we evaluated the ability of vimF mutant FLL476 to autoaggregate,
hemagglutinate and form biofilm. A four-fold increase in biofilm formation was observed
in FLL476 when compared to wild-type ATCC 33277 and the complemented strain
FLL476C’ (Fig. 2.2A). Also, autoaggregation was reduced in FLL476 when compared to
ATCC 33277 and FLL476C’, however the FLL476C’ did not totally regain its
autoaggregation ability (Fig. 2.2B). As shown in Fig. 2.2C., hemagglutination was totally
abolished in FLL476 when compared to hemagglutination titers of 32 and 64 for 33277
and FLL476C’, respectively.

65

B

A

3.00

2.00

OD=600nm

OD=595 nm

2.50

1.50
1.00
0.50

Time (minutes)

0.00
ATCC33277

FLL476

FLL476C'

1

1:2

Blank

1:8

1:4

C

1:16

1:32

1:64

1:128

33277
FLL476
FLL476C’
Blank
D

W83

*

*

FLL95

FLL476

ATCC 33277

Figure 2.2. Comparison of biofilm formation, autoaggregation, hemagglutination and invasion
assay. A. Biofilm formation of ATCC 33277, FLL476 and FLL476C’ were compared. Biofilm assay
was done by staining adherent cells of overnight cultures grown in microtiter plates with 0.5% (w/v)
crystal violet. Blank contained only media. Biofilm forming ability corresponded to OD595. B.
Autoaggregation of 33277, FLL476 and FLL476C’ corresponded to change in OD600 monitored for
about three hours after cells were washed and suspended in PBS. A representative sample is shown.
C. Hemagglutination activities of ATCC 33277, FLL476 and FLL476C’ were assessed by serially
diluting cells in PBS and incubating with sheep RBCs for 3 h at 4oC. Dilutions are listed above and
last dilution showing matt formation was taken as the titre. The blank contained only media. D.
Antibiotic Protection Assay was used to quantify invasion. P. gingivalis cells that were able to invade
HeLa cell monolayers were released by lysis and cultured on BA plates. Infectivity was taken as the
percentage of cells recovered. (* = p<0.05)
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VimF can Modulate the Invasive Capacity of P. gingivalis
HeLa cells incubated with P. gingivalis FLL95 and FLL476 showed a decrease in
invasion of approximately 45% compared to the wild-type (Fig. 2.2D). P. gingivalis
FLL95 complemented with the wild-type gene restored its invasive capacity similar to the
parent strain (data not shown).

The Cell Surface is Altered in the vimF-defective Isogenic Mutant
Electron microscopy was used to evaluate the cell surface ultra-structure of the
wild-type compared to the vimF-defective mutants. The wild-type W83 parent strain
revealed well defined outer membrane with outer membrane vesicles (Fig. 2.3) that were
missing in the isogenic mutant FLL95. The outer membrane and membrane vesicles was
restored in the complemented strain, FLL95C’. Electron micrographs of ATCC 33277
and its isogenic mutant FLL476 revealed a modified cell surface that was devoid of
fimbria in the FLL476 mutant. The wild-type phenotype was largely restored in the
complemented strains.

Cloning, Expression and Purification of rVimF
The vimF ORF was cloned into a His-tag containing expression vector. The
expected 50 kDa rVimF (47 kDa VimF and 3 kDa for the 6X Histidine tag) was not
observed to be secreted but was shown to co-purify with GroEL (60 kDa) only in cell
lysates. The purified rVimF protein showed a single band near the 50 kDa region (Fig.
2.4A). However western blot using anti-rVimF antibody showed reactive bands also at
100 kDa and 200 kDa regions (Fig. 2.4B). These two bands corresponding to the
multimeric forms of rVimF were confirmed using anti-rVimF antibodies and mass
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spectroscopy (data not shown). 2D gel electrophoresis of the purified rVimF showed
isoforms near the 50 and 100 kDa regions which were identified as VimF by mass
spectroscopy (data not shown). Since glycosylation of proteins is a common cause for the
isoforms observed in 2D gels, we used a glycoprotein stain to test whether rVimF was
glycosylated. When compared with positive and negative controls for glycoprotein
staining, rVimF did not take up the glycoprotein stain (Fig. 2.4D and C).

The Native VimF May be Post-Translationally Modified
Polyclonal antibodies raised against the gel purified rVimF immunoreacted with
multiple proteins bands representing the rVimF multimeric forms (Fig. 2.4B). Immune
serum did not immunoreact with any other protein (Fig. 2.4B). Similar immunoreactive
bands observed with the immune serum were missing using the pre-immune serum in
Western blot analysis (data not shown). To determine if the antibodies against the
recombinant VimF protein can recognize the native protein, cell lysates from P.
gingivalis were separated by SDS-PAGE and probed with the anti-rVimF antibodies. As
shown in Fig. 2.4E, immunoreactive bands from the P. gingivalis cell lysates were
missing using the immune serum. However, immunoreactive bands with sizes of 47, 60
and 80 kDa were observed when cell lysate proteins from W83 were first deglycosylated
then separated by SDS-PAGE and probed with the anti-rVimF antibodies (Fig. 2.4E).
The 47 kDa band corresponds to native VimF. Taken together, these results suggest that
differences may exist between the glycosylation of the native and recombinant VimF
protein. It is noteworthy that the rVimF was negative for glycoprotein stain (Fig. 2.4D).
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W83

ATCC 33277

FLL95

FLL476

FLL95-C

FLL476-C

Figure 2.3. Electron micrograph showing changes in surface structures of P. gingivalis ATCC
33277 and W83. Bacterial cells grown to the log phase (OD600 of 0.7 -0.9) were processed for
electron microscopic examination using formvar-carbon coated grids (500 mesh) and were
examined using Philips Tecnai 12 TEM. Fimbriae were lacking in the vimF mutant FLL476 when
compared with the wild ATCC33277 and the complemented strain FLL476C’. A thick glycocalyx
along with vesicles and a well-defined outer membrane was observed in W83. FLL95 showed hazy
outer membrane with reduced visicles. In the complemented strain FLL95C’ the outer membrane
morphology was restored.
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Figure. 2.4. 1D and 2D SDS-PAGE of rVimF. Purified rVimF was denatured in an LDScontaining buffer with DTT and heated for 10 min, and subjected to SDS-PAGE analysis. A.
Simply Blue Safe stain of rVimF at 2 different concentrations: lane 1 – 0.4 µg and lane 2 – 1.2
µg. B. Western blot using anti-rVimF antibody against purified rVimF showed reacting bands
at 50, 100 and 200 kDa. C. Simply blue safe stain of rVimF with horseradish peroxidase as
positive (PC) and soybean trypsin inhibitor as negative (NC) controls for glycoproteins. D.
Identical gel in panel C stained by periodic acid-Schiff (PAS) method for glycoproteins. E.
Western blot using anti-rVimF showed a 47 kDa reactive band only when total proteins of
W83 were deglycosylated and not with native (glycosylated) forms.
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rVimF Shows Galactosyltransferase Activity
VimF is annotated as a putative glycosyltransferase type 1
(http://oralgen.lanl.gov). Thus the activity of rVimF was evaluated using a calorimetric
assay [25] that exploits the lowering of pH resulting from the release of protons
associated with glycosyltransferase activity. The change in pH is detected
spectrophotometrically using a phenol red indicator. A calibration curve using known
concentrations of HCl was used to establish the relationship between proton release and
decrease in OD557 (Calibration curve). Commercially available UDP-galactose or UDPglucose as donor substrate and, glucose, galactose, mannose, N-acetylglucosamine or Nacetylgalactosamine as acceptor substrate, was used to screen for rVimF
glycosyltransferase activity. As shown in Fig. 2.5, the largest initial drop in OD557 was
observed when UDP-galactose (Fig. 2.5A) was used as the donor substrate as compared
to UDP-glucose as donor (Fig. 2.5B). Among the acceptor sugars used for UDP-galactose
as donor, glucose followed by N-acetyglucosamine showed the lowest OD557 in the time
course experiments suggesting their acceptor function in the presence of rVimF to these
two sugars. Therefore for activity assays we chose to use N-acetylglucosamine as it is
also the commonest acceptor used for commercially available β-1,4galactosyltransferases (Sigma, St. Louis, MO) which we chose as positive control. Lysate
from Top 10 cells was used as negative control.
Using UDP-galactose as donor and N-acetylglucosamine as acceptor the enzyme
activity of rVimF was calculated and compared with a commercially available β-1, 4galactosyltransferase. Fig. 2.6A shows a typical time trajectory of absorbance change
corresponding to rVimF-catalyzed proton release (higher the proton release lower the
OD557) in comparison to the positive and negative controls. Using the calibration curve,
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rVimF-catalyzed proton concentration change corresponding to the absorbance change
was calculated and plotted as a function of time (Fig. 2.6B). A linear regression was
performed (R2 = 0.9242) and the slope was estimated to be 0. 1797. The enzyme activity
of rVimF was calculated using the formula

0.1797mmol / L / min  1 10 3 L  0.1ml  1.797 mol / min/ ml
 1.797units / ml

Enzyme activity was defined as the amount of enzyme needed to produce 1 µmol of
proton per minute. Using the same formula, enzyme activities of the positive and
negative control was calculated to be 5.0 U/ml and 0.6 U/ml, respectively. Activity of
positive control, commercially available β-1,4-Galactosyltransferase, estimated by our
assay corresponds well with prescribed activity of > 0.6 U/ml suggested by the
manufacturer (Sigma, St. Louis, MO).
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Calibration curve
0.25
y=-0.001663x - 0.2196
R2 =0.9899
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Fig. 2.4.1 Calibration Curve. Relationship between proton concentration and OD557.
Different concentrations of hydrochloric acid (0 - 0.8 mM) in mixture containing 2 mM
phosphate, pH 8, 0.01 mM phenol red, 0.1 mM MnCl2, and 100 µl of rVimF lysate were
added and OD557 recorded.
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B

Figure 2.5. Screening for donor and acceptor substrates. Change of absorbance at 557
nm with time for A. UDP-galactose as donor and B. UDP- glucose as donor was plotted using
various sugars as acceptors. Lysates (100 µl) of expressing rVimF was used as enzyme
source and, lysates of Top 10 cells was used for negative control. The reaction mix contained
2mM phosphate, pH 8, 0.01mM phenol red, 0.1mM MnCl2, and 10 mM acceptor sugars. A
lower OD557 value was observed when UDP-galactose was used as the donor.
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Figure 2.6. Galactosyltransferase activity of rVimF. Activity of rVimF compared
with positive control (commercially available β- 1,4-galactosyltransferase) and
Negative control (non-specific E. coli Top 10 lysate). 100 µl of whole cell lysates of E.
coli containing pFLL477 expressing rVimF was added to reaction mix containing 2mM
phosphate, pH 8, 0.01mM phenol red, 0.1mM MnCl2, 10 mM N-acetylglucosamine and
UDP-galactose was added to start the reaction. OD557 was measured for 50 minutes. A.
Time course showing average of 3 independent assays. B. Activity of rVimF as a
galactosyltransferase was calculated by converting change in OD557 to amount of
proton release over time using the calibration curve in GraphPad Prizm 5 software.
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FLL95 Gingipain Proenzyme Did Not Show Glycan Attachment
To further clarify the role of VimF in the glycosylation of gingipains, the presence
of carbohydrates on the proenzyme gingipain species from FLL95 was determined using
SDS-PAGE glycoprotein stain. As shown in Fig. 2.7A, no detectable band was observed
in FLL95 in contrast to the gingipains from wild-type W83. For comparison a similar gel
stained with SimplyBlue SafeStain (Fig. 2.7B) is shown. A more sensitive technique
using methanolysis and silylation followed by GC-MS analysis of the TMS-methyl
glycosides confirmed the absence of any detectable sugar moiety attached to the
gingipain proenzyme species (data not shown). Taken together, these results suggest that
the proenzyme species from the vimF defective mutant is devoid of any detectable glycan
modification.
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Figure 2.7. FLL95 Gingipain proenzyme is devoid of carbohydrate
attachment. (A) Carbohydrate stain compared to (B) Simply Blue Stain of
W83 catalytic domain and FLL95 proenzyme: lane 1, positive control using
horseradish peroxidase provided by kit; lane 2, negative control using soybean
trypsin inhibitor provided by kit; lane 3, FLL95 proenzyme; lane 4, W83
catalytic domain.
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rVimF-Dependent Gingipain Glycosylation
In the P. gingivalis vimF-defective (FLL95) mutant the presence of the gingipain
proenzyme species and their lack of immunoreactivity to mAb 1B5 suggest a
glycosylation defect [12]. With the preference of rVimF to transfer galactose to Nacetylglucosamine, we evaluated its ability to transfer galactose to acceptor proteins in P.
gingivalis. In the presence of rVimF and UDP-galactose, a 60 kDa band that
immunoreacted with the glycan specific mAb 1B5 was observed in the extracellular
fraction of FLL95 (Fig. 2.8A). This band was missing in the absence of UDP-galactose or
when lysates of E. coli TOP 10 cells were used instead of rVimF in the reaction mixture
(Fig. 2.8B). Using mass spectroscopy this 60 kDa band was identified as Rgp
progingipain. A similar 60 kDa band in addition to a 45 kDa band was observed in the
extracellular fraction of W83 only when rVimF was present in the reaction mixture.
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Figure 2.8. In-vitro galactosyltransferase assay. Total cell lysate or extracellular
fractions from W83 and FLL95 were used as acceptor substrates, E. coli lysate carrying
pFLL477 served as its enzyme source and UDP-galactose served as donor substrate.
Western blots were probed with glycan specific mAb IB5. A. 60 kDa band appeared
when both UDP-galactose and rVimF enzyme lysate were present. B. Using
extracellular fractions of FLL95 as acceptor substrate a 60 kDa band was seen only
when rVimF lysate and UDP-galactose were present. Negative control using Top 10 E.
coli lysate did not show the 60 kDa band.
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Table 2.1. Plasmids and Bacterial Strains Used
Plasmid/Strains

Phenotype and description

Reference

pTrcHis2 TOPO

ampr, lacIq

Invitrogen

pFLL477

pTrcHis2 TOPO containing the vimF This study
gene

Plasmid

Bacterial Strains
P. gingivalis
W83

Wild type

(Abaibou, 2001)

FLL95

vimF mutant in W83

(Vanterpool, 2005)

FLL95C’

Complemented FLL95

This study

ATCC 33277

Wild type

FLL476

vimF mutant in ATCC 33277

This study

FLL476C’

Complemented FLL476

This study

E. coli
DH5α

F-Φ80dlacZΔ M15 Δ(lacZYA-argF) Invitrogen
U169 recA1endA1 hsdR17 (rk-, mk+)
phoA supE44 λ-thi-1 gyrA96 relA1

Top10

F-mcrA
Δ(mrr-hsdRMS-mcrBC) Invitrogen
Φ80dlacZΔ M15 ΔlacX74 recA1
ara139Δ(ara-leu)7697 galU galK rpsL
(StrR) endA1 nupG
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Table 2.2. Primers Used for the construction of mutants
Primer

Description

Sequence

P1

vimF forward

5'-ATGAAACGGGTACTCATCTTCGCCGA-3'

P2

vimF reverse

5'-GTTAGCGACGATCGATTCCAGTAGAC-3'

P3

vimF-1Kb
upstream
vimF-erm
reverse

5'-CGGGAAGAGAGTCCTTGCTTTTCAAAGCA-3'

P5

vimF-erm
forward

5'-TTCGTAGTACCTGGAGGGAATAATCATTCAGCAT
CGTATCATGAAGTAC-3'

P6

vimF-1Kb
downstream
erm_F
forward

5'-CTGCAGTACGGGCACGGTTG -3'

P8

erm_F
reverse

5'-GATTATTCCCTCCAGGTACTACGAAGGATGAAATTTTTCA3'

P9

vimF
complement
forward
vimF
complement
reverse

5'-GAT CGG AAA GCA GCG CAA GCG ACT TAT-3'

P4

P7

P10

5'-GTCATTTATTCCTCCTAGTTAGTCATGGTCGATGG
CCGTTTCGTAGTCG-3'

5'TGACTAACTAGGAGGAATAAATGACAAAAAAGAAATTGC
CCG-3'

5'-ATC TGT CGA ACT CCG GAC TGC CG-3'
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Discussion
Proteolytic processing and glycosylation are important components in the
maturation/activation/anchorage of the gingipains in P. gingivalis [38]. In this report we
have used both genetic and biochemical approaches to further confirm the role of specific
bacterial host factors in gingipain biogenesis. Several recent studies have identified the
involvement of many nongingipain genes in this process [39–44]. In addition a conserved
C-terminal domain (CTD) is essential for the secretion and attachment of the gingipains
to the cell surface [45]. Collectively, an emerging picture from these studies suggests a
complex process that is facilitated by the appropriate glycosylation of the gingipains.
Glycosylation is a recently identified post-translational modification of proteins in
prokaryotes [19]. This process which involves the enzymatic attachment of a glycan
moiety to a protein is known to influence biological properties like activity, solubility,
folding, conformation, stability, half-life, and/or immunogenicity [46,47]. Since the
initial report of the S-layer glycoprotein of archaea Halobacterium halobium (salinarum),
some of the well-known examples of bacterial glycoproteins belong to genera
Campylobacter, Mycobacterium, Neisseriae, Pseudomonas, Chlamydiae, Escherichia
and Porphyromonas [7,19]. In P. gingivalis, a defect in several GTases including Rfa,
UgdA, GtfA, GtfB have been shown to affect polysaccharide biosynthesis that have
resulted in decreased gingipain activities [11,17,18]. VimF, which is annotated as a
putative glycosyltransferase (www.oralgen.lanl.gov) has been shown to be involved in
maturation of gingipains, hemolysis, hemagglutination and fibronectin cleavage similar
to some of the other GTase-defective mutants previously described [12,48]. In this study,
several of these phenotypic characteristics were confirmed in a different P. gingivalis
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genetic background. These observations further support the vital role of VimF in the
pathogenesis of P. gingivalis.
Compared to the wild-type, the growth rate and gingipain activity were reduced in
the vimF-defective mutants in both genetic backgrounds. However, the gingipain activity
in P. gingivalis FLL476 was reduced by approximately 60% compared to more than 90%
reported in P. gingivalis FLL95 [12]. This observation could suggest the role of
additional factor(s) that may be involved in the maturation/glycosylation of the
gingipains. For example, a functional homologue of vimF or an alternate
glycosyltransferase, which is more effective in the P. gingivalis 33277 genetic
background could be responsible for the increased activity. There are multiple
glycosyltransferases reported in P. gingivalis (http://www.cazy.org/), however the
substrate specificity for several of these enzymes is unknown.
The invasive capacity of the vimF-defective isogenic mutant in multiple genetic
backgrounds was reduced compared to the wild-type. This was not unexpected, given the
cell surface alterations in the vimF-defective mutants. This alteration in cell surface is
also thought to contribute for the increased biofilm formation observed in FLL476.
Similar observations have been reported[16,49]. The role of fimbria in host cell invasion
by P. gingivalis is well documented [50]. In the vimF-defective isogenic mutant, the
phenotypic expression of fimbria appeared to be altered. In addition it is known that a
defect in LPS biosynthesis in P. gingivalis can influence attachment of the gingipains to
the cell surface, autoaggregation, and biofilm formation. These phenotypic properties are
known to be associated with P. gingivalis invasive capacity.
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We have observed that the His-tagged rVimF, a 50 kDa protein, is
homotetrameric and, on 2D gel showed isoforms. Purified rVimF was observed as a
single band (Fig. 2.4A). However, the same gel, when subjected to western blot analysis
and probed with anti-rVimF antibody showed immune reactivity to three different bands
corresponding to 50 kDa, 100 kDa and 200 kDa (Fig. 2.4B). This seemingly conflicting
observation is possible as rVimF may not be completely denatured in the presence of
10% SDS. The multimeric rVimF forms are consistent with the 200 kDa band observed
in a native gel. Isoforms observed on the 2D gel is likely due to post-translational
modifications of the rVimF protein. The type of modification is under further
investigation.
In P. gingivalis, the anti-rVimF antibody immunoreacted with multiple protein
bands only after deglycosylation. The 47 kDa protein band is the expected size of the
VimF product and likely suggests that it’s a glycoprotein. The 60 and 80 kDa
immunoreactive bands may have conserved domains that can cross react with the antirVimF antibody although we cannot rule out mutimeric forms of VimF. Further
investigation of their identity and possible function is underway.
The P. gingivalis vimF gene encodes for a 47 kDa protein that has
galactosyltransferase activity. This, possible multimeric protein, was demonstrated to
have the ability to transfer UDP-galactose to N-acetylglucosamine. VimF, which may
also be a glycoprotein, is suggested by these studies to play a specific role in gingipain
glycosylation. In contrast to the vimA-defective mutant which only had the RgpB
gingipain cell associated, or other GTase-defective mutants that are missing any cellassociated gingipain, the vimF-defective mutants had both cell and extracellular
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associated inactive forms of the gingipains [43,44,51]. Throughout all the growth phases,
no activation of the gingipains was observed. Variation in the glycosylation profile of the
gingipains including the missing phosphorylated branched mannan was also noted
[44,52] in the vimF mutants. In the presence of rVimF and UDP-galactose, a 60 kDa band
identified as RgpB regained its missing phosphorylated branched mannan. This could
imply that galactose is important for the addition of the glycan moiety carrying the
phosphorylated branched mannan. The monosaccharide composition of the gingipains
from P. gingivalis W50 is known to include arabinose, rhamnose, fucose, mannose,
galactose, glucose, GalNAc, GlcNAc, and N-acetylneuraminic acid [13]. There also
appears to be common steps in the synthesis of LPS and APS and the maturation of the
gingipains [13,52,53]. A bioinformatic analysis of the Rgp-gingipains predicted two
potential O-linked and 15 potential N-linked glycosylation sites for RgpA. This is in
contrast to RgpB that was predicted to have 6 N-linked and no O-linked glycosylation
sites. Reported elsewhere, the sugars in RgpA are thought to be present predominately
in O-linked chains with the monosaccharide GalN(Ac) linked to Ser/Thr [13]. Most Nlinked glycan chains occur via N-acetylglucosamine attached to asparagine and followed
sequentially by hexoses such as galactose [54]. The results from this study suggest that
galactose is vital for the growing glycan chain. Because the gingipains from the vimFdefective mutant were missing any detectable carbohydrate modifications, this raises
questions regarding the monosaccharide protein link. While we cannot rule out an Nacetylglucosamine link, as observed in Haemophilus, it is likely that galactose can
occupy these N-linked sites [55]. It is also unclear if the attachment of these glycans
occurs either sequentially or en-block. Further, in these experiments it was unclear if the
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gingipain could complete the maturation process and gain proteolytic activity. This is
under further investigation in the laboratory.
Our observation that the inactive proenzyme species can be cell associated in the
vimF-defective P. gingivalis strain raises questions on the specific glycosylation
requirement for attachment. Further, based on previous reports, the posttranslational
proteolytic processing of the gingipains involves multiple enzymes for their activation.
RgpA and Kgp are known to require a surface located carboxypeptidase for activation in
contrast to RgpB which is known to require a novel C-terminal signal peptidase [56,57].
It is clear from our studies that the appropriate glycosylation may be a prerequisite for
proteolytic processing and the addition of galactose may occur early in the sequence.
In conclusion, we have presented in vitro evidence for posttranslational regulation
of proteolytic activity in P. gingivalis. In vitro glycosyltransferase activity for rVimF
was observed using UDP-galactose and N-acetylglucosamine as donor and acceptor
substrates, respectively. Further, in the presence of the rVimF protein and UDPgalactose, the glycosylation of the RgpB proenzyme was restored. Together, these
observations suggest the VimF glycoprotein is a galactosyltransferase that may be
specific for gingipain glycosylation. Moreover, galatose is vital for the growing glycan
chain. This model system will facilitate a more careful evaluation of glycosylation
occurring in gingipain biogenesis in P. gingivalis. Components of this system could
possibly be an important therapeutic target.
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CHAPTER THREE
A POLYCLONAL RABBIT ANTI-rVIMF MADE TO LOCALIZE VIMF IN P.
GINGIVALIS SHOWED POTENTIAL TO STUDY HEMAGGLUTINATION
DOMAIND OF GINGIPAINS

Abstract
Hemagglutination/adhesion domains play vital role in pathogenesis of
Porphyromonas gingivalis, an important etiological agent of adult periodontitis. Among
the three types of gingipains namely, RgpA, RgpB and Kgp, hemagglutination domains
are present only in RgpA and Kgp. We have shown that the vimF was able to transfer
galactose to gingipains. In order to localize VimF among sub cellular fractions we raised
an anti-rVimF antibody. We observed that this polyclonal rabbit antibody was not able to
react with native VimF from P. gingivalis W83. However, using less stringent western
blotting conditions this antibody was able to react to a 40 and 42 kDa protein only from
outer membrane and outer membrane vesicle proteins of P. gingivalis W83 and not from
FLL95, the vimF mutant. Mass spectrometry done on these proteins identified the 40 kDa
protein as Kgp and the 42 kDa band as RgpA. Further only a single immunoreactive band
was observed from FLL374 and FLL372, the Kgp and RgpA mutants respectively. Taken
together the ability of anti-rVimF antibody to react with hemagglutinin domains of RgpA
and Kgp could be used to study hemagglutinin domains of gingipains. Further, a VimF
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chimeric strain having an extra copy of vimF with a 6X His tag, was constructed to
localize VimF. This strain could also be used to study the biology of native VimF.

Introduction
P. gingivalis, the primary pathogen implicated in adult periodontitis is able to
produce, among others, potent protease called gingipains which, like any other protease,
is produced in an inactive form and post translationally processed to become
mature/active gingipains. Among the three types of gingipain produced by this organism,
namely RgpA, RgpB and Kgp, RgpB lacks the hemagglutination/adhesin (HA) domains
that are found between the catalytic and the C terminal domain in both RgpA and Kgp
[1,2]. Figure 3.1 shows various domains of gingipains. The HA domains are important
for growth of this bacterium as this domains, anchored to the bacterial LPS, mediate
assimilation of hemin, an iron containing porphyrin which is a vital ingredient for
survival of this organism [3]. Recent studies have shown that RgpA and Kgp have
multiple HA domains. It is shown that RgpA consists of a N terminal signal peptide
followed by pro-peptide and the catalytic proteinase domain (42-kDa) and
hemagglutination/adhesion domains at the C terminus, named HGP44, HbR, HGP17,
HGP27 (previously called RgpA44, RgpA15, RgpA17, RgpA27), respectively [1,4,5].
Kgp also consists of similar domains (Fig. 1). Interestingly, the hemagglutinin/adhesion
domains are also encoded by the hemagglutinin gene hagA with similar C-terminal
regions (HGP44 and HbR). Further it is shown that the HA domains contain repeated
adhesion binding motifs mediating binding to host proteins including fibronectin,
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Figure 3.1. Gingipains and HagA Show Domain Homologies. RgpA and Kgp consist of
signal peptide (sp), propeptide (pro), proteinase and adhesion domains (HGP44, HbR,
HGP17, and HGP27). R and K indicate cleavage sites for Rgp and Kgp, respectively.
RgpB lacks HGP44 and HbR domains. Reproduced from Sakai E et.al [5].
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fibrinogen and type IV collagen [6]. The Hgp domain has been reported to adhere to
collagen and fibronectin, which are intracellular matrix components [6]. Moreover, Rgp
is linked to processing of fimbrilin and other surface proteins [7-9]. Although various
studies have implicated HA domains for hemagglutinating activity [10,11], direct
evidence of the molecule that exhibit hemagglutination and adhesion has not been
obtained. Further, the steps involved in the processing of this HA domains are poorly
understood.
In addition it was shown that RgpA-Kgp complexes (otherwise called highmolecular-weight gingipains) encoded by rgpA and kgp are major virulence factors in the
pathogenicity of P. gingivalis W50 [12]. This observation has been verified as mutants of
these genes had attenuated virulence in rat periodontitis models and, vaccines against
these complexes were able to protect the rats against challenge [13,14]. Further studies
have shown that these high molecular weight membrane associated mt-RgpAcat and
HRgpA are glycosylated [15,16]. Although one study has shown the role of RgpB in
glycosylation of these proteins, the amount of glycosylation seen in these proteins (14% 30%) suggest role of other genes including glycosyltransferases that may be involved in
processing of these forms of gingipains [17,18].
Glycosylation in bacteria is now a well-accepted post-translational modification
and both N and O- glycosylations have been reported from bacteria [19]. While it is well
accepted that glycosylation occurs in the endoplasmic reticulum and the Golgi of
eukaryotes, in bacteria, which lack these organelles, it is not clear where glycosylation
occurs [20]. However, starting from the first observation of the S-layer glycoproteins of
Halobacterium halobium (salinarum), the list of bacterial glycoproteins has been growing
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long [21]. Bacterial glycoproteins now includes gingipains of P. gingivalis in which
about 14 – 30 % by weight is due to carbohydrates [17].
Although more than 20 glycosyltransferase genes are present in the genome of P.
gingivalis W83, only a few have been characterized. All of the glycosyltransferases
investigated from P. gingivalis so far (gtfA, gtfB, PG0106 and vimF), have been shown
to be closely associated with pathogenic abilities. In the gtfB mutant there was complete
loss of surface-associated gingipain proteinases, autoaggregation and biofilm formation
due to defective O-LPS and A-LPS biosynthesis [22]. In the PG0106 mutant (which is
closely related to vimF phylogenetically and involved in capsular biosynthesis) there was
an increase in auto-aggregation and biofilm formation suggesting surface variations
leading to this phenotype [23]. In gtfA mutant, the major fimbriae was not mature leading
to decrease in auto aggregation and attachment to epithelial cells suggesting role in
pathogenicity by regulating adhesion [24]. Finally, reduced autoaggregation, increased
biofilm formation, reduced gingipain activity that were secreted, and abolition of
hemagglutination activity were also observed in the vimF mutant of W83 [25] and ATCC
33277 (FLL95 and FLL476. Ref, 2nd chapter) suggest their role in pathogenicity.
Although we have shown that VimF is involved in glycosylation of arginine specific
gingipains, we were led to evaluate their role in glycosylation of other P. gingivalis
proteins.
While evaluating the polyclonal rabbit antibody raised primarily against rVimF,
we noted its inability to bind to native VimF unless it was first deglycosylated,
suggesting differences in glycosylation machinery between and P. gingivalis despite the
fact that rVimF produced from showed in-vitro enzymatic activity. In this chapter we
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present our observations that under reduced stringency levels anti-rVimF antibody could
cross-react with a 40, 42 and 80 kDa proteins seen only on outer membrane and outer
membrane vesicle fractions of P. gingivalis W83 and not in the vimF mutant FLL95.
Furthermore, mass spectrometric analysis of the reactive protein bands from various
subcellular fractions of W83 and FLL95 were identified. In addition, we present the
initial characterization of a vimF chimera (FLL479), which contained an extra copy of
vimF at the fimA site along with a N-terminal 6X His tag. This strain was engineered to
purify native VimF from P. gingivalis W83, ascertain its function as a glycosyltransferase
and also to localize the VimF protein among P. gingivalis subcellular fractions.

Materials and Methods
Bioinformatic Analysis of VimF
Using the amino acid sequence retrieved from from Oralgen
(http://www.oralgen.lanl.gov) the secondary structure prediction and modeling of protein
was done using Modeler 9v8 and validated using WHATIF program [26,27]. The signal
peptide and potential cleavage sites were predicted using both the neural network and
hidden Markov model [28]. Bioedit (http://www.nbio.ncsu.edu/bioedit/bioedit.html), the
online biological sequence alignment editor, was used to align amino acid and DNA
sequences retrieved from Oralgen database. Phylogenetic relationship and distance was
calculated using MEGA version4.0 and Kimura 2- parameter model, and clustering the
neighbor-joining method was employed using boot strap values based on a thousand
replicates [29,30].
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Bacterial Growth Conditions
Strains of P. gingivalis used in this study listed in Table 3.1. were grown in brain
heart infusion (BHI) broth (Difco Laboratories, Detroit, MI) supplemented with 5 g/ml
hemin, 0.5 g/ml vitamin K and 0.1% cysteine. Five percent agar and 5% sheep blood
were added to make blood agar (BA). Ten g/ml of erythromycin was used to select
resistant colonies. All cultures were incubated at 37oC in an anaerobic chamber (Coy
Manufacturing, Ann Arbor, MI) with 80% nitrogen, 10% carbon dioxide and 10%
hydrogen.

Cell Fractionation
The cytoplasmic, inner membrane (IM), outer membrane (OM), Vesicle (V) and
particle free culture supernatant fractions were separated as previously reported with few
modifications [31,32]. Briefly, cells grown to late log phase were centrifuged for 30 min,
at 10,000g to separate cell pellet from the culture medium. Supernatant containing culture
medium was then ultra-centrifuged at 100,000g for 60 min at 4oC. Resulting pellet was
re-suspended in 10 mM Tris HCl (pH 7.4) and considered as the vesicle fraction (Ves),
and the ammonium sulphate precipitated (80%) supernatant resuspended in 10 mM Tris
HCl (pH 7.4) was considered as particle free supernatant containing the extracellular
fraction (Ext). Cell pellet was washed thrice with 1X PBS and resuspended in PBS
containing 0.1mM N-p-tosyl-L-lysine chloromethyl ketone (TLCK), 0.1 mM leupeptin,
and 0.5 mM EDTA. Cells were then lysed using French press (American Instrument
Company, Silver Spring, MD) in the presence of protease inhibitor by 5 passes. After
removing the bacterial cell debris by centrifuging at 10,000g for 20 min, the supernatant
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was ultra-centrifuged at 100,000g for 60 min at 4oC. While resulting supernatant was
ammonium sulphate precipitated and considered as the cytosolic fraction (Cyto), the
pellet was treated with 1% Triton-X-100 in PBS containing 20 mM MgCl2 for 30 min at
20oC and ultra-centrifuged at 100,000g for 60 min at 4oC. While the precipitate was
considered as the outer membrane (OM) fraction the supernatant was concentrated as
taken as inner membrane (IM).

SDS-PAGE and Western Blot
The different cell fractions were subjected electrophoresis, either in denaturing
conditions in a standard 10% SDS-PAGE procedure or in the native conditions omitting
SDS, reducing agent (DTT) and anti-oxidant in morpholineethanelsulfonic acid (MES)
buffer as reported [25]. About 20 to 40 g of protein was used for electrophoresis.
Separated proteins were transferred on to nitrocellulose membrane using Semi-Dry
Trans-blot (Bio-Rad) at 15V for 25 min. The blots were then probed with polyclonal
rabbit anti-VimF antibody in either the stringent or less stringent conditions. For the less
stringent conditions both blocking buffer and washing buffer contained 0.5 M NaCl
instead of regular 1.3 M NaCl, 3% BSA was used in place of 5% milk, primary antibody
was allowed to react for 1.5 hrs instead of 1 hr and washing after primary antibody was
done only twice instead of four in the stringent conditions. Incubation with secondary
antibody conjugated with HRP was for 30 minutes followed by two washing and finally,
5 minutes treatment with visualizing Chemiluminescence Reagent Plus kit (Perkin-Elmer
Life Science, Boston, MA) followed by exposure to film were the same for both
stringency conditions. Anti-RgpA antibody was used following stringent conditions.
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Tryptic Digestion and Mass Spectrometry
SDS-PAGE separated protein bands and spots from 2D gels were excised and
subjected to digestion with trypsin. The gel slices were first transferred to low retention
epi vials (Fisher, Hampton, NH) and dehydrated using neat acetonitrile for 30 minutes. 20
µl of TCEP (tris(2-carboxyethyl)phosphine) was then added and incubated for 1 hr at
60oC. In the next step, 40 µl alkylating buffer (200 mM iodoacetamide) was added and
incubated at room temperature for one hour. The gel slice was washed in 0.5 ml of neat
acetonitrile and re-suspended in another 0.5 ml of neat acetonitrile to dehydrate. Next,
digestion buffer containing mass spectrometry grade trypsin in 50 mM NH4HCO3 was
added to attain a 1:20 to 1:50 enzyme/substrate ratio and incubated overnight at 40oC.
Digestion was stopped using 10 µl of 10% formic acid. Digested peptides were extracted
using standard Zip Tip (C18) technology (Millipore, Bedford, MA) according to
manufacturer’s protocol. MS analysis of extracted peptide was done as described
elsewhere [33].

Localization of VimF in P. gingivalis by Immunogold Staining
Anti-VimF antibodies were purified and used at a working concentration of
1: 1000. The colloidal gold conjugate (10 nm; Aurion) was diluted using incubation
buffer (20 mM phosphate buffer, 150 mM NaCl pH 7.4, 0.2 % BSA, 15 mM NaN3) to
1: 1000. A checkerboard titration of primary antibody to immunogold conjugate was
made to identify the optimal working concentration. Processed nickel grids were
subjected to charging of the processed P. gingivalis strains for 1 h, then washed 20 times
in 0.025 M Tris buffer (pH 7.4) and lightly blotted. Grids were subsequently blocked
with 5 % BSA in 0.025 M Tris buffer for 15 min at room temperature, then incubated in
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diluted antibody–gold complex for 4 h at 37 °C. Staining was done using uranyl acetate
(0.8 g uranyl acetate dissolved in 10 ml absolute ethanol) and freshly prepared lead
citrate (10–40 mg lead citrate, 10 ml filtered water, 100 μl 10 M NaOH). Grids were
immersed in uranyl acetate for 7 min at room temperature and then washed, once by
immersion in 25 % ethanol and twice by immersion in water. Grids were dried on filter
paper for 10 min at room temperature and then floated on lead citrate drops for 5 min.
Following two washes by immersion in 0.02 M NaOH and drying, grids were visualized
using the Philips Tecnai FEI-12 TEM.

Construction of vimF Chimera
We used the PCR-based fusion of purified overlapping PCR amplified DNA
fragments, a method described earlier [34], to insert vimF gene with an N terminal 6XHis tag and ermF which was amplified from pVA2198 into the fimA site. Primers used
are listed in Table 3.2. Briefly, 1 kb fragments upstream and downstream of fimA were
amplified using primers specifically designed to render amplicons with overhangs (Table
3.2). Four fragments namely, 1 Kb upstream of fimA, vimF with N-Terminal 6X His tag,
ermF and 1 Kb downstream of fimA were amplified using primers designed to have
overhangs complementary to adjacent oligomers. After purification these fragments were
mixed in a reaction and subjected to 25 cycles of renaturing and annealing in the presence
of PCR reaction mix without primers. Subsequently, one microliter of the sample was
used in a PCR reaction using only P1 and R4 to get the fusion. Electrophoresis was used
to ascertain the 3.5 Kd size of fused fragments. Fused PCR fragments were
electroporated into P. gingivalis grown to the log phase as previously described [35].
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Cells were then plated on to BHI agar containing 10 g/ml erythromycin and incubated at
37oC for seven days. Colonies containing the correct gene replacement, as confirmed by
colony PCR and DNA sequencing, were selected for further analysis.

Results
Structure Analysis of VimF
Bioinformatics analysis of VimF revealed beta sheets sandwiched by alpha
helices that face each other, a structure consistent with glycosyltransferases. Figure 3.2
shows the following observations: An N-terminal signal peptide suggestive of the
secretory nature of this protein, potential cleavage site between position 16 and 17 at the
N terminal end suggestive of N terminal cleavage, two stretches of signature peptides
(196 - 213 and 244 - 261) spanning the conserved structural motif were noted. The
structure of the protein showed (Fig. 3.3) no membrane helix that suggests its localization
on membrane or vesicles. Further a C terminal peptide suggestive of site of attachment to
other proteins was noted. Phylogenetic analysis of all the glycosyltransferase-I in P.
gingivalis W83 genome (Figure 3.4) revealed homology between VimF and PG0106, a
glycosyltransferase linked to capsular polysaccharide synthesis [23]. Interestingly this
protein is predicted to localize in the cytoplasm (www.stdgen.lanl.gov).
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Figure 3.2. Amino Acid Sequence of VimF Showing Unique Signatures Peptides
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Figure 3.3. Model of VimF Showing Signature Peptides and Domains.
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Figure 3.4. Phylogenetic Analysis of P. gingivalis Glycosyltransferase I Showed
That vimF (PG0884) had Highest Homology to PG0106.
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Anti-rVimF Antibody Did Not React With Native VimF
Polyclonal rabbit antibody raised against recombinant VimF was evaluated for
reactivity with total cell lysates of W83. Figure 3.5 A and B shows the ability anit-rVimF
antibody to react specifically with rVimF and its inability to react with any proteins from
total cell lysates of P. gingivalis W83. However, as reported in chapter two, we have
observed a 50 kDa reactive band when deglycosylated proteins of W83 whole cell lysates
were immunoreacted with anti-rVimF antibody. When less stringent western blotting
conditions was used, both pre-immune (Fig. 3.5C) and immune serum showed identical
immunoreactive protein bands against P. gingivalis subcellular fractions although the
bands appeared less prominent in the pre-immune serum.

Rabbit Anti-rVimF Reacts With 40, 42, 80 and 17 kDa Protein Bands
in Denaturing Conditions
Figure 3.6 show the ability of anti-rVimF antibody to react with faint 17 kDa and
29 kDa proteins, well-defined 40 and 42 kDa proteins, and a diffuse well defined 80 kDa
protein only from outer membrane and outer membrane vesicle fractions of W83 and not
from FLL95. When FLL95 absorbed anti-rVimF was used in western blot the 29 kDa
band seem to disappear. In addition subcellular fractions when electrophoresed under
non-reducing conditions resulted in a single band around the 250 kDa which reacted with
anti-rVimF in the western blot. Mass spectrometric analysis of the 40 and 42 kDa protein
identified these proteins to be Kgp (PG1844) and RgpA (PG2024).
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A
80 kDa
50 kDa
25 kDa

B
100 kDa
50 kDa

D

C

Figure 3.5. Under Stringent Conditions Anti-rVimF Antibody That Immunoreacted With
rVimF Did Not React With Proteins from W83. A. SDA-PAGE of rVimF, total cell lysates of
W83 and FLL95 at different concentrations of protein. B. Western using anti-rVimF
antibody. Western using preimmune serum C. and Immune serum D. reacted with
subcellular fractions of W83.
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A
150 kDa
80 kDa
60 kDa
50 kDa
40 kDa

30 kDa
25 kDa
20 kDa
15 kDa
10 kDa

B
80 kDa

60 kDa
50 kDa
40 kDa
30 kDa
25 kDa
10 kDa

Figure 3.6. Anti-rVimF Reacted With 40 and 42 kDa Bands in Less Stringent Conditions.
Various sub-cellular fractions: Cyto= cytoplasm, IM = inner membrane, OM=outer
membrane, Ves=Vesicle and Ext=extracellular were subject to A. SDS-PAGE and B.
blotted and probed with anti-rVimF antibodies at less stringent conditions showing the
40 and 42 kDa band from outer membrane and Vesicle fraction of P. gingivalis W83.
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A Single Band Was Observed From kgp and rgpA Mutants
To further confirm the ability of anti-rVimF antibody to react with hemagglutinin
domains of RgpA and Kgp we repeated the western blot using the anti-rVimF antibody
against subcellular fractions of FLL374 and FLL372, the Kgp and RgpA mutant
respectively. Figure 3.7A shows SDS-PAGE of subcellular fraction of the mutants. Only
a single 42 kDa immunoreactive band was observed from outer membrane and vesicle
fractions of FLL374 (Fig. 3.7B), the kgp mutant. Similarly, a single 40 kDa
immunoreactive band was also observed from outer membrane and vesicle fractions of
FLL372 (Fig. 3.7B), the rgpA mutant. These observations highlight the ability of
antibody raised against rVimF to immunoreact with the 40 and 42 kDa hemagglutinin
domains of P. gingivalis W83.

Immune Electron Microscopy (IEM) Using Anti-rVimF Antibody
Immunogold staining (Fig. 3.8) showed attachment of gold particles to the
external surface of W83 especially surrounding the secreted vesicular structures during
log phase. However, attachment of antibody tagged gold nanoparticles was not identified
in FLL95 mutant. It is noteworthy that FLL95 did not produce any significant secretory
vesicles. We also noted immunotagged gold nanoparticles only to wild type W83 cell
suggesting the role of VimF glycosyltransferase in matured, secreted gingipain vesicles.
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FLL374

FLL372

A
80 kDa
50 kDa

40 kDa
30 kDa
25 kDa

B
60 kDa
50 kDa
40 kDa
30 kDa
25 kDa

Figure 3.7. The kgp and rgpA Mutants Reacted With Single Band Near the 40 kDa Region.
Western blot of sub-cellular fractions of kgp and rgpA mutants (FLL374 and FLL372
respectively) probed with anti-rVimF antibody showed single band from the outer
membrane and vesicle fractions. A. SDS-PAGE gel of cytosolic (Cyto), inner membrane
(IM), outer membrane (OM) and vesicle (Ves) fractions of kgp and rgpA mutants.
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W83

FLL95

Figure 3.8. Immune Electron Microscopy Using Anti-rVimF Antibody Showing Immunogold
Particles Attached to Vesicles of W83 but Absent in FLL95, the vimF mutant.
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Construction of FLL479, the VimF Chimera
The 1 Kb upstream of fimA, vimF with N-terminal His tag, ermF and 1 Kb down
stream of fimA were amplified separately in different PCR reactions (Fig. 3.9A). After
purification the four fragments were mixed and subjected to 25 cycles of denaturing and
annealing steps in a thermal cycler. Subsequently one microliter of this mix was used for
PCR amplification in the presence of primers P1 and R4. As shown in Fig. 3.9B, the
fusion fragment (3.5 Kb) was purified and electroporated into P. gingivalis W83 and
incubated. Colonies were screened for the 3.5 Kb insert using primer P1 and R4 (Fig.
3.9C) and one colony containing this insert was called FLL479 and chosen for further
evaluation. DNA sequencing confirmed the successful insertion of the purified construct
into the fimA site.

Growth Characteristics, Gingipain, Biofilm and Hemagglutination
Assays of FLL479
Similar to P. gingivalis W83, colonies of FLL479 were black pigmented and hemolytic
on blood agar. Growth characteristic, proteolytic ability, and hemagglutination activity of
FLL479 were also measured. Although growth curve (Fig. 3.10 A) and Rgp activity (Fig.
3.10 B) was similar to the wild type W83, a small increase in the Kgp activity (Fig. 3.10
B) was observed. Further, an increase in hemagglutination titer was observed for the
VimF chimeric strain from various repeated measurements (Fig. 3.10 C).
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Figure 3.9. Construction of vimF Chimera. A. About 1 kb upstream and downstream of
fimA, target containing vimF with N-terminal His tag and ermF were amplified in
separate PCR reactions. B. Shows the fusion of the four fragments resulting in the 3.5 kb
fragment. C. Screening of colonies for the insert showed one colony (lane7) containing
the correct insertion.
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Figure 3.10. Characterization of FLL479, the VimF Chimera: A. Growth curve – OD600
was measured at intervals of time over a period of 24 hours. B. Gingipain assay – Rgp and
Kgp activity were measured in whole cell cultrures grown to stationary phase. Gingipain
activities of W83 were normalized to 100% to compare with the chimera. C.
Hemagglutination assay – Serially diluted cells were incubated with sheep RBC in a roundbottom microtiter plates for 3 hours at 4oC.
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Table 3.1. Strains of P. gingivalis and Plasmid Used

Strain/plasmid

Phenotype and description

Source

W83

Wild type

[35]

FLL95

VimF-defective

[25]

FLL374

Kgp-defective

This study

FLL372

rgpA-defective

This study

FLL479

vimF-chimera

This study

pVA2198

Spr, ermF-ermAM

[8]
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Table 3.2. Oligoneucleotide Primers Used for the Construction of FLL479
Primer

Sequence (5’ – 3’)

P1

ACAAGTACCCCATCCTAAAAAGTCGA

R1

GTTTATGATGATGATGATGATGCATCTCGTTTTTGTTTTAAAAGTG

P2

ATG CAT CAT CAT CAT CAT CAT AAA CGG GTA CTC ATC TTC GC

R2

CCATTTATTCCTCCTAGTTAGTCATTAGTTAGCGACGATCGATTCCAG

P3

TGACTAACTAGGAGGAATAAATGGAGAAAAAAATCACTGGAT

R3

GATTATTCCCTCCAGGTATTACGCCCCGCCCTGCCACT

P3

TACCTGGAGGGAATAATCTCGACCCGTCAAACGACTAAAAA

R4

GTCTGGGGCCATTAGCTTCCAG
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Discussion
Bioinformatic analysis predicted VimF to be a glycosyltransferase-I with a B type
fold. Although bioinformatics analysis show N terminal signal peptide motif suggestive
of protein export through the conventional pathway, our earlier studies expressing the
VimF protein in did not show the protein secreted, contrarily it was seen in the
cytoplasm. Also it is noteworthy that VimF expressed in showed different
posttranslational modification since an antibody raised against rVimF failed to react with
native VimF from P. gingivalis. The closest phylogenetic neighbor PG0106 has been
implicated in the synthesis of capsular polysaccharide [23]. This further stresses the role
of glycosyltransferases in cell surface structures. However, further investigations are
needed to implicate the role of native VimF in cell surface modification. In addition it
will be worthwhile to investigate interacting protein partners, which will underline the
involvement of VimF in cell surface biogenesis.
Although a polyclonal antibody raised against rVimF reacted well with rVimF
from, it could not react with any protein from total cell lysates of P. gingivalis W83.
However, the fact that reduced stringent immunoblotting conditions were able to react
with hemagglutinin domains of Kgp and RgpA, suggest either a similarity between
rVimF and the hemagglutinin domains of these proteins or a non-specific rabbit antibody
to these domains. The later is probably the case as sequence alignment revealed no
similarity between hemagglutinin domains and VimF, and, both pre immune and immune
serum reacted with these protein bands. Also, it is possible that anti hemagglutinin
antibodies can be made by animals as they are naturally exposed to various viruses that
use hemagglutinins as target for attachment to host cells thus gaining access into the host.
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Evaluation of anti-rVimF antibody against cytoplasmic and extracellular fractions
revealed their ability to immunoreact with Kgp and RgpA domains. This was further
confirmed as from rgpA defective mutant (FLL372) only the 40 kDa Kgp reacted with
anti-rVimF and, from the kgp defective mutant (FLL374) only the 42 kDa RgpA
immunoreacted with anti-rVimF antibody.
Owing to the cross-reactivity of anti-rVimF to HA domains in less stringent
western blotting conditions it became difficult to draw clear conclusions of our results
from the immune electron microscopy experiments. We observed strong reaction of antirVimF conjugated gold particles with vesicles from W83. These experiments, however,
were done under routine IEM conditions. Given our observation that anti-rVimF antibody
cross-reacts with HA domains, it is possible that we are observing the same cross
reactivity.
Alternate ways to localize VimF have to be attempted as anti-rVimF antibody
showed non-specific cross-reactivity with other proteins. Given our observation (chapter
2) that deglycosylated protein fractions could react with anti-rVimF in the stringent
western blotting conditions, we will test the reactivity of the antibody with
deglycosylated subcellular fractions of W83 and compare it with the FLL95. Further, we
will use FLL479, the VimF chimera, which has an extra copy of the VimF in the fimA
site to these localization studies. Additionally as this strain contains a 6X His tag on the
N-terminal, we could also use a anti-His antibody to localize this protein at the
subcellular level.
Initial characterization of VimF chimeric strain FLL479 showed no significant
differences in growth characteristics and Rgp activity. However there was correlation
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between the increase of Kgp activity to the increased hemagglutination observed. We
have used W83 as positive control, although the ideal control should be the FimA mutant,
as this is the site where the extra copy of vimF was inserted. However, even if the FimA
mutant had been used, we would only expect to see a hemagglutination activity that
would be lesser than W83. Contrarily we observed an increase in hemagglutination
activity.

Conclusion and Future Directions
We initially raised the anti-rVimF antibody aiming to use it for localization of
VimF protein in the subcellular fractions of P. gingivalis, thereby being able to
understand the compartment where glycosylation may be taking place within the bacterial
cell. However, polyclonal rabbit anti-rVimF antibody was not able to immunoreact with
native VimF. Contrarily under less stringent conditions it seem to cross react with
hemagglutinin domains of gingipains. Also in-silico protein sequence alignment study
between VimF with RgpA, Kgp and HagA domains did not show any significant
similarity. Taken together it is possible that this rabbit serum contained anti
hemagglutinin antibodies. We therefore plan to purify this antibody against rVimF using
affinity column. Secondly, we will use the FLL479, the VimF chimera, to purify VimF in
the native state, raise antibodies and use them to investigate the subcellular localization of
VimF. On the other hand, using our observation that the anti-rVimF antibody was able to
react with deglycosylated protein fractions, we will use W83 and FLL479 subcellular
fractions to localize the protein. These investigations will broaden our understanding on
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the biology of VimF, and other important proteins involved in maturation/activation of
gingipains, leading to use of this protein as a future therapeutic target.
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CHAPTER FOUR
FINAL DISCUSSION

Among the several important pathogenic bacteria implicated in adult
periodontitis, P. gingivalis plays a central role as the keystone pathogen orchestrating
other bacteria of the oral microbiota to produce the highly destructive periodontal disease
which leads to exfoliation of teeth [1]. Gingipains, the cysteine proteases, represent one
of the many important virulence factors responsible for pathogenic success of this
organism [2]. vimF is one of the important genes of the vim locus involved in the posttranslational modification of gingipains leading to its maturation/activation. Based on
sequence similarity, VimF displays molecular relatedness to glycosyltransferases and is
classified as glycosyltransferase I. Inactivation of this gene resulted in reduction of
gingipain activity by more that 90%. In addition, the vimF mutant (FLL95) showed
reduced hemagglutination and the inactive gingipains were not found attached to the cell
[3]. Glycosylation as a post-translational modification of virulence factors has been
shown to play a pivotal role in survival, virulence and pathogenesis of microorganism
[4].
Cell-surface structures of organisms are decorated with sugars/glycans, one of the
four fundamental building blocks of life besides proteins, nucleic acids and lipids [5].
Glycosylation, the process by which glycans are attached to proteins, is an important
post-translational modification of living cells and glycoproteins are increasingly reported
in prokaryotes [4]. In contrast to glycation, which is a non-enzymatic chemical reaction,

127

glycosylation is an enzyme-directed site-specific molecular process catalyzed by
glycosyltransferases. Glycosylation in bacteria have been accepted only recently and both
N-glycosylation and O-glycosylation has been reported in pathogenic bacteria[6,7] with
either sequential transfer of glycans or en-block transfer of glycans to amino acids [7].
Further, unlike synthesis of nucleic acids and proteins, branching is a common feature in
glycan synthesis and each step is mediated by a glycosyltransferase. In addition,
glycosylation has been reported to be closely associated with the pathogenic potential of
P. gingivalis [3,8-10]. However, detailed investigations of this complex process with
regard to transfer of glycans in relation to donor and acceptor specificities have not been
investigated in P. gingivalis. We have cloned vimF, purified and raised polyclonal
antibody to this protein, evaluated its glycosyltransferase function and report its ability to
transfer galactose to arginine specific gingipains (Rgp). In addition, our investigation
suggests that VimF is a glycoprotein as well.
Further to playing an important role in post-translational modification of
gingipains via glycosylation VimF is also involved in the modification of surface
structures of P. gingivalis. We have shown that, in addition to reduced gingipain activity
and growth characteristics, FLL476, the vimF mutant in ATCC 33277 background,
showed reduced auto-aggregation and total inability to agglutinate sheep RBCs.
However, there was an increase in biofilm-forming ability in this mutant. Such an
increase in biofilm forming ability has also been previously observed in the vimA mutant
of ATCC 33277 [11]. These observations strongly suggest the involvement of mature
forms of gingipains on the cell surface in reduced auto-aggregation, lack of
hemagglutination and change in biofilm-forming capacity observed among the vim
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mutants. Additionally, defects in fimbrial and cell wall LPS synthesis have also been
shown to influence attachment of gingipains to the cell surface, autoaggregation and
biofilm formation [12]. These phenotypes are important for the invasive capacity of P.
gingivalis.
Immature gingipains (pre and pro gingipains) undergo extensive processing
before becoming mature gingipains [13]. Of the three types of gingipains, namely RgpA,
RgpB and Kgp, both RgpA and Kgp are known to contain hemagglutinin/adhesion (HA)
domains [14]. While studies have shown that HA domains mediate binding to host
proteins such as fibronectin, fibrinogen and typeIV collagen which are all components of
cellular matrix, the role of these domains, and their ability to function in the incompletely
processed gingipains it is not clear [15]. It is therefore possible that HA domains of
gingipains may also mediate auto-aggregation and hemagglutination. Further, our
observation that the vimF mutants in both genetic backgrounds were non-black
pigmented on BHI blood agar suggest its role in hemin assimilation. Such phenotypic
variation were shown to be a function of the HA domains [12]. These surface
modifications ultimately decrease the capacity of the vimF mutants to invade cells,
suggesting an overall role of VimF in pathogenicity. These VimF mediated surface
modifications were evident as shown in the electron micrographs of the vimF mutants
compared to their respective wild-types (chapter 2). Fimbrial structures were missing in
FLL476 (33277 background) and vesicles were not found in FLL95 (W83 background).
It is noteworthy that gingipains are also necessary for processing of fimbriae [16]. Taken
together, we have highlighted the role of VimF in the modification of surface structures
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by documenting changes in the vimF mutant strain in a different genetic background of P.
gingivalis.
We were able to clone and purify the recombinant VimF and raise polyclonal
antibodies to this protein. Although anti-rVimF antibody reacted specifically to rVimF,
the native VimF from P. gingivalis was not recognized by these antibodies unless first
deglycosylated, suggesting VimF to be a glycoprotein. Post-translational modifications
are observed as protein isoforms on a 2D gel electrophoresis [17]. We observed such
isoforms when purified rVimF was subjected to 2D gel electrophoresis. Given that
glycoslyctransferases can themselves be glycoproteins [18], and our observation that
deglycosylated native VimF from P. gingivalis reacts with anti-rVimF antibody strongly
suggests that VimF is a glycoprotein. rVimF was not glycosylated when expressed in E.
coli because of the lack of glycosylation machinery in this bacteria. However
glycoproteins could be expressed in E. coli when genes comprising glycosylation islands
from other bacteria were engineered into them [19,20]. Therefore, to further understand
the biology of native VimF, we have constructed a chimeric strain having an extra copy
of the vimF gene in the fimA locus of W83. Studies using this chimeric strain to purify
native VimF and raise antibody are currently underway.
We have reported galactosyltransferase activity of rVimF in spite of the
glycosylation deficiency observed in rVimF. This observation suggests that the activity of
rVimF is not contingent on the proper glycosylation of different domains of this protein.
While some of the reported galactosyltransferases have been expressed and purified in E.
coli without difficulty, others have been challenging [21-24]. In one study involving a
galactosyltransferases from Salmonella enterica, it was shown that the C-terminal
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domain was enough to exhibit the galactosyltransferase function [21]. We therefore think
that either the glycosylation defect we have observed did not affect the function of rVimF
or that the activity we observed may be the attenuated activity due to the glycosylation
defect. The fact that galactosyltransferase are important in pathogenic bacteria is
highlighted by several reports of galactosyltransferases from these bacteria [21-25].
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Figure 4. Model showing VimF mediated glycosylation of
gingipains in P. gingivalis
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We have demonstrated the galactosyltransferase activity of VimF by two different
methods. In the first method the activity of rVimF was measured by a calorimetric assay.
This assay showed the preference of rVimF to transfer UDP-galactose over UDP-glucose
in the presence of N-acetylglucosamine. In the second method, a phosphorylated
mannose specific antibody reacted with a 60 kDa band in the extracellular fraction of
FLL95 only after incubation with rVimF and UDP-galactose. This observation highlights
the important role galactose plays in the growing glycan chain (Fig. 4). Since glycan
addition can be either sequential or en bloc, we are not sure what the case may be for the
rVimF mediated transfer. Further studies need to be done to understand the prerequisite
of such a VimF mediated reaction. However, the VimF mediated glycosylation via
galactose transfer seem to be crucial as without this step subsequent addition of glycans,
including phosphorylated mannose does not appear to be possible. This crucial step
mediated by VimF makes it an interesting target for therapy. Although it has been
previously reported that galactose is a major glycan present on RgpA [26] the exact
position that galactose occupy in the glycan chain is not known. Finally, it is clear from
our studies that the appropriate glycosylation may be a prerequisite for proteolytic
processing of gingipains and the addition of galactose may occur early in the process.
Linkage and sequence analysis of glycans attached to gingipains will shed more light on
specific linkage(s) and position of galactose. Such studies are currently underway in our
lab.
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